Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 1 (94)   Clinical Study Protocol  
 Drug Substance  Olaparib  
 Study Code  <<>>  
 Version  4.0 
 Date  11/23/2020  
 
 
 Temozolomide and Olaparib for O6-Methyguanine DNA Me thyltransferase 
Promoter Hyperm ethylated Colorectal Cancer  
    
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 2 (94)  VERSION HISTORY 
Version 4.0, 11/23/2020  
Version 1.0, 6/6/19  
Version 2.0, 8/1/19 
Version 3.0, 8/26/2019 
Version 3.1, 11/11/19 
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 3 (94)  TABLE OF CONTENTS  
TITLE PAGE  ........................................................................................................... 1 
VERSION HISTORY  .............................................................................................. 2 
TABLE OF CONTENTS  ......................................................................................... 3 
1. PROTOCOL SUMMARY ....................................................................................... 8 
1.1 Schedule of Activities (SoA)  ................................................................................... 8 
1.2 Synopsis  ................................................................................................................. 14 
1.3 Schema  ................................................................................................................... 18 
2. INTRODUCTION  ................................................................................................. 19 
2.1 Study rationale  ....................................................................................................... 20 
2.2 Background  ............................................................................................................ 20 
2.3 Benefit/risk assessment  .......................................................................................... 23 
2.3.1  Potential benefits and risks for olaparib  ................................................................. 23 
2.3.2  Potential benefits and risks for temozolomide  ....................................................... 24 
3. OBJECTIVES AND ENDPO INTS  ....................................................................... 25 
4. STUDY DESIGN  ................................................................................................... 26 
4.1 Overall design  ........................................................................................................ 26 
4.2 Safety Evaluation Period  ........................................................................................ 27 
4.3 Dose Limiting Toxicity Definition  ........................................................................ 27 
4.4 Scientific rationale for study design ....................................................................... 28 
4.5 Justification for dose  .............................................................................................. 28 
4.6 End of study definition ........................................................................................... 29 
5. STUDY POPULATION  ........................................................................................ 29 
5.1 Inclusion criteria  .................................................................................................... 29 
5.2 Exclusion criteria  ................................................................................................... 31 
5.3 Lifestyle restrictions  ............................................................................................... 33 
5.3.1  Meals and dietary restrictions  ................................................................................ 33 
5.3.2  Activity  .................................................................................................................. 33 
5.4 Screen failures  ........................................................................................................ 34 
6. STUDY TREATMENTS  ....................................................................................... 34 
6.1 Treatments administered  ........................................................................................ 34 
6.1.1  Investigational products  ......................................................................................... 34 
6.2 Preparation/handling/storage/accountability  .......................................................... 35 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 4 (94)  6.3 Measures to minimise bias: randomisation and blinding ....................................... 36 
6.4 Treatment compliance  ............................................................................................ 36 
6.5 Concomitant therapy  .............................................................................................. 36 
6.5.1  Background medication ......................................................................................... 40 
6.5.2  Other concomitant treatment  .................................................................................. 40 
6.6 Dose Modifications  ................................................................................................ 40 
7. DISCONTINUATION OF T REATMENT AND PATIENT  
WITHDRAWAL  .................................................................................................... 42 
7.1 Discontinuation of study treatment  ........................................................................ 42 
7.1.1  Procedures for discont inuation of study treatment  ................................................ 42 
7.2 Lost to follow -up .................................................................................................... 43 
7.3 Withdrawal from the study  .................................................................................... 43 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................................. 44 
8.1 Efficacy ass essments  .............................................................................................. 44 
8.2 Safety assessments  ................................................................................................. 46 
8.2.1  Clinical safety laboratory assessments  ................................................................... 46 
 Coagulation  ............................................................................................................ 47 
 Bone marrow or blood cytogenetic samples  .......................................................... 47 
8.2.2  Physical examinations  ............................................................................................ 47 
8.2.3  Vital signs  .............................................................................................................. 47 
8.2.4  Electrocardiograms  ................................................................................................ 48 
8.2.5  Other safety assessments  ........................................................................................ 48 
 Serum or urine pregnancy test  ............................................................................... 48 
8.3 Collection of adverse events  .................................................................................. 49 
8.3.1  Method of detecting AEs and SAEs  ...................................................................... 49 
8.3.2  Time period and frequency for collecting AE and SAE information .................... 49 
 Adverse events after the 30 day follow up period  ................................................. 49 
8.3.3  Follow -up of AEs and SAEs  .................................................................................. 50 
8.3.4  Adverse event data collection  ................................................................................ 50 
8.3.5  Causality collection  ................................................................................................ 51 
8.3.6  Adverse events based on signs and symptoms ....................................................... 51 
8.3.7  Adverse even ts based on examinations and tests  ................................................... 52 
8.3.8  Hy’s law  ................................................................................................................. 52 
8.3.9  Disease pr ogression  ............................................................................................... 52 
8.3.10  New Cancers  .......................................................................................................... 52 
8.3.11  Lack of efficacy  ..................................................................................................... 53 
8.3.12  Deaths  .................................................................................................................... 53 
8.3.13  Olaparib adverse events of special interest  ............................................................ 53 
8.4 Safety reporting and medical management  ............................................................ 53 
8.4.1  Reporting of serious  adverse events ....................................................................... 53 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 5 (94)  8.4.2  Pregnancy  ............................................................................................................... 54 
 Maternal exposure  .................................................................................................. 54 
 Paternal exposure  ................................................................................................... 55 
8.4.3  Overdose  ................................................................................................................ 55 
8.4.4  Medication error  ..................................................................................................... 56 
8.4.5  Management of adverse events related to Olaparib and TMZ  ............................... 56 
 Management of haematological toxicity  ................................................................ 57 
Management of anaemia  ......................................................................................................... 57 
Management of neutropenia, leukopenia and thrombocytopenia  ........................................... 58 
Management of prolonged haematological toxicities while on study treatment .................... 58 
 Management of non -haematological toxicity  ........................................................ 59 
Management of new or worsening pulmonary symptom  ....................................................... 59 
Management of nausea and vomiting  ..................................................................................... 59 
Interruptions for intercurrent non- toxicity related events  ....................................................... 60 
 Renal impairment ................................................................................................... 61 
8.5 Pharmacokinetics  ................................................................................................... 61 
8.6 Pharmacodynamics  ................................................................................................ 61 
8.7 Genetics  .................................................................................................................. 61 
8.7.1  Collection of optional genetic samples  .................................................................. 61 
8.7.2  Storage and destruction of genetic samples  ........................................................... 62 
8.8 Biomarkers  ............................................................................................................. 62 
8.8.1  Storage, re- use and destruction of biomarker sam ples .......................................... 64 
9. STATISTICAL CONSIDER ATIONS  ................................................................... 64 
9.1 Statistical hypotheses  ............................................................................................. 64 
9.2 Sample size determination  ..................................................................................... 64 
9.3 Populations for analyses  ........................................................................................ 65 
9.4 Statistical analyses  ................................................................................................. 66 
9.4.1  Efficacy analyses .................................................................................................... 66 
9.4.2  Safety analyses  ....................................................................................................... 67 
9.4.3  Other analyses  ........................................................................................................ 67 
9.4.4  Methods for multiplicity control  ............................................................................ 67 
9.5 Interim analyses  ..................................................................................................... 67 
9.5.1  Data monitoring committee (DMC)  ....................................................................... 67 
9.5.2  Safety Monitoring .................................................................................................. 68 
10. REFERENCES  ...................................................................................................... 69 
11. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  ............................................................................................. 80 
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 6 (94)  LIST OF TABLES  
Table 1  Schedule of Activities  ................................................................................. 9 
Table 2  Objectives and endpoints  .......................................................................... 16 
Table 3  Study Treatments  ...................................................................................... 34 
Table 4  Prohibited medications  ............................................................................. 37 
Table 5  Restricted concomitant medications  ......................................................... 37 
Table 6  Dose reductions for olaparib to manage adverse events ........................... 40 
Table 7  Dose reductions for TMZ t o manage adverse events  ............................... 41 
Table 8  Dose reduction for olaparib if patient develops moderate renal 
impairment ................................................................................................ 41 
Table 9  Dose reductions for olaparib if patient has to start taking a strong 
or moderate CYP3A inhibitor  .................................................................. 41 
Table 10  Laboratory safety variables  ...................................................................... 46 
Table 11  Management of anaemia  ........................................................................... 57 
Table 12  Management of neutropenia, leukopenia and thrombocytopenia  ............. 58 
Table 13  Dose reductions for study treatment  ......................................................... 60 
Table 14  Dose reductions for study treatment  ......................................................... 61 
 
LIST OF FIGURES  
Figure 1  Study des ign ............................................................................................. 18 
Figure 2        Overview of three key a lkylation damage repair pathways …………….21 
LIST OF APPENDICES  
LIST OF APPENDICES   
Appendix  A Actions required in cases of increases in liver biochemistry and evaluation of Hy’s Law  ............................................................................ 81 
Appendix B  Adverse event definitions and additional safety information  ............ 86 
Appendix  C Acceptable Birth Control Methods  ........................................................... 91 
Appendix  D ECOG Performance Status  ....................................................................... 93 
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 7 (94)   
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 8 (94)  1. PROTOCOL SUMMARY  
1.1 Schedule of Activities (SoA)  
The proc edures for the screening and treatment periods in this study are presented in Table 1 . 
For olaparib treatment  
• Patients may delay dosing under certain circumstances  
− Dosing may be delayed per the Dosing Modification and Toxicity Management 
Guidelines (see section 8.4.5)  due to adverse events (AE)  
− If dosing must be delayed for reasons other than treatment -related toxicity, 
dosing will resume as soon as feasible.  
− In the event that olaparib is discontinued or de layed as part of the toxicity 
management guidance, TMZ may still be administered as scheduled.  
For Temozolomide (TMZ) treatment  
• Dosing may be delayed per the Dosing Modification and Toxicity Management Guidelines (see section 8.4. 5) due to AEs.  
− If dosing must be delayed for reasons other than treatment -related toxicity, 
dosing will resume as soon as feasible.  
− In the event that TMZ is discontinued or delayed as part of the toxicity management guidance, olaparib may still be administered as scheduled.  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 9 (94)  Table 1 Schedule of Activities  
Tests  Screening   
Treatment Period  (Each cycle repeats every 21 days)  End of 
Treatmenta Safety 
Follow
-upm Long Term 
Follow -upb 
Cycle 1  Cycle 2  Cycle 3  Cycle 4  Cycle 5 and beyond     
Day -28 
to -1 D1 
± 3 
days  
  D8 
± 3 
days  
 D15 
± 3 
days  
 D1 
± 3 
days  
 D 15  
± 3 
days  
 D1 
± 3 
days  
 D15 
± 3 
days  
 D1 
± 3 
days  
 D15 
± 3 
days  
 D1 
± 3 days  
 D15 
± 3 days  
    
Administrative Procedures  
Informed 
Consent  X               
Inclusion / Exclusion Criteria  X               
Demographics and Medical History  X               
Prior and Concomitant Medication Review  X X  X X X X X X X X  X X  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 10 (94)  Clinical Procedures / Assessments  
Review Adverse 
Events  X X X X X X X X X X X  X X X 
Full Physical Examination  X X           X   
Directed Physical Examination    X X X X X X X X X   X  
Vital Signs and 
Weightc X X X X X X X X X X X  X X  
ECOG PSd X X X X X X X X X X X  X X  
Post Study 
Anti-cancer 
Therapy Status              X X X 
Adverse Event 
Recording   X X X  
Long Term 
Follow -Up     X 
SAE Recording   X X X X 
Treatment / Supportive Care Administration  
Olaparib   Continuous administratione    
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 11 (94)  Temozolomide   Xe   Xe  Xe  Xe  Xe     
Laboratory Procedures / Assessments  
Pregnancy Test  Xf Xf   Xf  Xf  Xf  Xf     
Clinical 
chemistryo X Xg Xg Xg Xg  Xg  Xg  Xg  X   
CBC with 
differential  X Xg Xg Xg Xg  Xg  Xg  Xg  X   
PT/INR and 
aPTTp X               
Urinalysis  X X              
CEA  X X   X  X  X  X     
TSH  Xh        Xm       
EKG Xn               
Efficacy Measurement / Imaging  
CT Chest / Abdomen / Pelvis  X
i Response assessment imaging will be performed every 6 weeks (+/3 days)j Xk  Xk 
Tumor Biopsies/Correlative Studies Blood  
Biopsyl X            X   
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 12 (94)  Research Blood 
collection  Xr X X X X  X  X    X X  
Stool Sample  Xq      Xq         
a. An end of treatment visit will be done within 7 days after progression of disease or discontinuation of study treatment for other reasons, and an additional follow up 
visit at 30 ± 7 days post discontinuation. In the case that the patient initiates a subs equent anti -cancer therapy, the 30 day follow up should occur prior to the first dose of 
the new therapy and the patient will move to long term follow up.  
b. After the end of treatment visits the subjects will enter long -term follow up during which informa tion on survival and subsequent anticancer therapy will be obtained by 
phone every 12 weeks until the subject dies, is lost to follow up, or withdraws consent. Patients who come off study for reas ons other than disease progression should be 
assessed in the  clinic an d radiographically every 6 weeks ( ± 7 days) for  the first year and 12 weeks ( ± 7 days) after the first year.  
c. Vital signs should include temperature, pulse, respiratory rate, weight and blood pressure. Height will be measured on day 1 only. For  cycles 2 and beyond, vital signs 
may be perform ed up to 2 days before Days 1 and/or 15.  
d. For treatment cycles 2 and beyond, physical examination, ECOG performance status, weight/BSA may be performed up to 2 days before Days 1 and/or 15.  
e. Olaparib will be taken continuously at a starting dose of 150 mg twice daily on days 1- 21; Temozolomide will be taken days 1 -7 every 21 days at a starting dose of 75 
mg/m2. 
f. A pregnancy test at screening and on Day 1 is only required for women of “child bearing poten tial” as defined in the inclusion criteria . If required, the pregnancy test 
prior to cycle 1 may be done up to 72 hours prior to the treatment of study medications.  A pregnancy test is required on day 1 for each cycle (+/ - 72 hours) for women of 
“child bea ring potential.”  
g. For cycle 1 pre- treatment labs should be drawn within 24 hours prior to study treatment. After cycle 1, pre -treatment labs can be drawn up to 72 hours pre -dose.  
h. TSH  (reflex T3, FT4 ) will be drawn at screening and  prior to treatment with cycle 4 , and every 4 cycles thereafter (i.e. cycle 8, cycle 12, cycle 16 , etc…)  
i. A ba seline CT scan will be done –  28 to -1 days prior to study treatment.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 13 (94)  j. Response assessment CT scans will be performed at the end of cycle 2 and at the end of every subsequent second treatment cycle at day 18 +/ - 3 days (i.e. Days 15 to 
21 of cycles 2, 4, 6, 8 and beyond). After 12 cycles, if disease is stable or improving, imaging will be performed in the same m anner after every third cycle.  
k. Patients who come off study for reasons other than disease progression will continue to undergo a CT Chest / Abdomen / Pelvis every 6 weeks ( ± 7 days) for the first 
year and every 12 weeks  (± 7 days) after 1 year.  
l. A mandatory pre -treatment biopsy will be required for al l patients if deemed to be low risk and safe in the opinion of the treating investigator. An optional treatment 
biopsy after disease progression will also be obtained.  
m. A safety follow up visit will be scheduled 30 days ± 7 days post discontinuation. If  the patient is to start a new therapeutic agent prior to this 30 -day period, the safety 
follow up visit must take place before the subsequent agent is given. Follow up visits will then be every 8 weeks post discon tinuation.  
n. An EKG will be done at screening and as clinically indicated while on study. If abnormalities on EKG are noted an echocardiogram maybe performed as clini cally 
indicated.  
o. Refer to section 8.2.1 for specific laboratory variables to be drawn.  
p. Patients who are taking warfarin may  participate in this trial; however, it is recommended that INR be monitored carefully at least once per week for the first mo nth, 
then monthly if the INR is stable.    
q. Refer to the lab manual for stool collection instructions.    
r. For patients undergoing tumor biopsy and patient derived xenograft generation, 2 additional research tubes may be collected during screening around the time of biopsy 
as outlined in the lab manual.  
 
 
 
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 14 (94)  1.2 Synopsis  
Principal Investigator  
Michael Cecchini  
Yale Cancer Center  
Yale School of Medicine  
333 Cedar Street  
New Haven CT 06510  
USA 
 
Statistician  
Daniel Zelterman  
Yale School of Public Health 
60 College St  
New Haven CT 06520  
PO Box 208034 Office: (203) 785 -5574  
Fax (203) 785- 6912  
Daniel.zelterman@yale.edu  
Protocol Title: Temozolomide and Olaparib for O
6-Methyguanine DNA Methyltransferase 
Promoter Hyperm ethylated Colorectal Cancer  
Short Title:  TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer  
Rationale :  
Colon cancer is the third most common cancer in the United States, and it accounts for 9% of all 
cancer related deaths (Cronin et al. 2018) . Systemic medical therapy is essential in management 
of these patients. Over the last two decades a number of available systemic treatments have 
improved both quality of life and overall survival, which now exceeds 2 years for sta ge IV 
disease (Loupakis et al. 2014a) . However, the optimal sequence for the use of the available drugs 
is not clear and exposure of all of the active a gents seem to be more important than the order of 
administration. Hence, the more lines of therapy we can offer to patients, the more benefit 
patients can derive in terms of their survival  and quality of life. E ffective biomarkers are lacking 
for CRC.  
Howe ver, O6-methylguanine DNA methyltransferase (MGMT) promoter hypermethylation is 
described in up to 40% of colorectal adenocarcinoma in prospective studies as well as subsets of gastric, pancreatic, and neuroendocrine tumors where it has been associated wit h increased 
sensitivity to TMZ and dacarbazine (Thomas 2017, Bae 2002, Konduri 2009, Esteller 1999, Kulke 2009, Walter 2015) . Promoter hypermethylation of MGMT is most widely described in 
glioma and when companied by CIMP, almost universally results in MGMT promoter 
methylation in these tumors (van den Bent 2013, Clark 2016, Noushmehr 2010, Turcan 2012) . 
Promoter hypermethylation ultimately causes decreased MGMT expression and renders these 
tumors more susceptible to TMZ (Chinot 2007, Br andes 2006, Hegi 2005) . The monofunctional 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 15 (94)  alkylator, TMZ causes three common types of alkylation DNA damage, which are depicted in 
Fig 2 . The MGMT protein is the major pathway for the removal of 06 -methylguanine lesions, 
which are extremely toxic in replicating cells and is frequently silenced by promoter 
hypermethylation in many cancers, either focally or as a result of CIMP. Additionally, a major 
mechanism for repair of N7 -methylguanine and N3 -methyladenine lesions is by base excision 
repai r, which is blocked by treatment with PARP inhibitors.  
Inhibitors of base excision repair and MGMT have been shown to sensitize tumors to TMZ (Delaney 2000, Trivedi 2005, Barvaux 2004, Hermisson 2006, Yan et al. 2007, Luo 2004, Liu et 
al. 2003) . Tumor sensitivity to TMZ is increased in combination with PARP inhibitors in cell 
lines and xenografts both in  vitro  and in  vivo  (Smith et al. 2015, Tentori e t al. 2003, Palma et al. 
2009, Gill et al. 2015b, Delaney 2000, Jagtap and Szabó 2005, Tentori et al. 2001a, Tentori et al. 2001b, Calabrese et al. 2004, Curtin et al. 2004) . Furthermore, the PARP inhibitor, veliparib, 
reverses TMZ resistance in multiple xenografts of various tumor  types (Palma et al. 2009) . As 
stated above the base excision repair pathway is an important pathway for demethylation, 
however the increased TMZ sensitivity with PARP inhibitors is likely multifactorial (Jagtap and Szabó 2005, Boulton et al. 1995) . For example, stalled replication forks are typically overcome 
by HR DNA repair, but PARP inhibitors can delay the initiation of this HR -mediated recovery 
(Cimprich and Cortez 2008, Yang et al. 2004, Lavin 2008) . In addition, PARP trapping appears 
to be critical for improving TMZ sensitivity, which makes olaparib an ideal PARP inhibitor to 
use in combination with TMZ (Murai et al. 2014b, Pommier, O’Connor and de Bono 2016, 
Murai et al. 2012a) . The combination of TMZ with PARP inhibitors has  gained traction with 
multiple ongoing clinical trials evaluating various combination in multiple diseases 
([STUDY_ID_REMOVED], NCT0215982, [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED] and others) 
(Ohmoto and Yachida 2017)  and specifically the TMZ olaparib combination has been deemed 
safe and worthy of further evaluation in both GBM and small cell lung cancer in various dosing schemes (Farago et al. 2018, Fulton et al. 2017, Halford et al. 2017) . 
Temozolomide has activity in the relapsed / refractory setting for CRC, likely related to the high prevalence of MGMT promoter hypermethylation in this disease, which is supported by 
prospective clinical trials.  Based on TMZ resistance mechanisms described, preliminary data 
suggests the addition of PARP inhibitors can lead to a sustained anti -tumor response and 
appropriate safety data to support this combination is available. T herefore we  propose a 
biomarker driven, open- label clinical trial with TMZ in co mbination with the poly ADP ribose 
polymerase (PARP) inhibitor olaparib for MGMT promoter hypermethylated CRC. 
Table 2. Objectives and endpoints:  
Primary objectives:   Endpoints/variables:  
To determine the efficacy of TMZ in 
combination with olaparib in subjects with 
MGMT promoter hypermethylated advanced 
colorectal cancer by the overall response rate 
(ORR)  ORR by RECIST v1.1 criteria  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 16 (94)  Secondary objectives:  Endpoints/variables:  
To determine the safety of TMZ in 
combination with olaparib  Rate of ≥ grade 3 adverse  events  by CTCAE 
v5.0 
To estimate the progression free survival 
(PFS)  PFS 
To estimate overall survival (OS)  OS 
Exploratory objectives:   Endpoints/variables:  
Characterize NGS profiling, patterns of DNA  
methylation, gene express ion, and develop 
MGMT expression assays Association of NGS profiling, patterns of 
DNA methylation, gene expression, and 
develop MGMT expression assays with 
efficacy and clinical parameters.  
Correlate molecular features with γH2AX 
with response  Association of γH2AX  with response rate and 
survival endpoints  
Establish organoids for MGMT promoter  
hypermethylated colorectal cancer  Form a library of colorectal cancer organoids  
Overall design:  
This is a Phase II, non- randomized, open- label, single -institution study to evaluate temozolomide 
in combination with olaparib in patients with MGMT promoter hypermethylated advanced 
colorectal cancer.  Potentially eligible patients will be tested for MGMT promoter 
hypermethylation by methylation specific PCR af ter signing a pre -screening consent. The study 
will begin with a safety evaluation period to assess for dose limiting toxicity (DLT) in the first 6 treated patients, and if toxicity is observed a dose de -escalation schema will be considered.  
Study period:   
Estimated Date of First Patient Enrolled: January 2020  
Estimated Date of Last Patient Completed: January 2022  
Number of patients:  
The study will enroll 30 patients to receive temozolomide + olaparib combination therapy every 
3 weeks (q3w). Patients will  provide a tumor tissue sample at screening to determine MGMT 
promoter hypermethylation by methylation -specific polymerase chain reaction (PCR) analysis.  
Treatments and treatment duration:  
Systemic therapy:  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 17 (94)  Temozolomide + Olaparib: Temozolomide (75 mg/m2 orally on days 1- 7 every 3 weeks) + 
Olaparib (150 mg orally twice daily days 1- 21) in a 21- day cycle.  
Duration of treatment:  
Treatment will continue until disease progression, unacceptable adverse event(s), withdrawal of 
consent or death. 
Progression du ring treatment:  
During the treatment period, patients who have Response Evaluation Criteria in Solid Tumors, 
version 1.1 (RECIST 1.1) defined radiological progression will proceed to follow -up. Patients 
with equivocal progression who are clinically stable  may continue on treatment phase of the 
study at the discretion of the patient and Investigator until progression is confirmed, no earlier than 4 weeks after and preferably within 4 to 6 weeks after the prior assessment of progression of 
disease.  
Follow -up of patients post discontinuation of study drug:  
Patients who have discontinued study treatment due to toxicity or symptomatic deterioration, clinical progression/recurrence, or who have commenced subsequent anticancer therapy will be followed until RECIST 1.1 -defined progression of disease and then at least for an additional 8 
weeks with at least 1 additional follow up scan or death (w hichever comes first). A repeat 
optional tumor biopsy will be done at the time of disease progression unless it is de emed 
clinically unsafe to perform.  
Survival:  
All patients in the study should be followed up for survival.  Independent data monitoring committee:  
The principal investigator and Yale Center for Clinical Investigation (YCCI) are responsible 
for monitoring  the performance of the study. The Yale Cancer Center Data and Safety 
Monitoring Committee (DSMC) will provide primary oversight of data and safety monitoring. The Yale DSMC will review and monitor compliance, toxicity and deviations 
from this study. The c ommittee is composed of clinical specialists with experience in 
oncology and who have no direct relationship with the study. Information that raises any 
questions about participant safety will be addressed with the Principal Investigator. The DSMC will rev iew this protocol at a minimum of once every six months.  
Statistical methods  
We anticipate about 20% of those screened will exhibit an appropriate biomarker as well as meet 
eligibility criteria. To obtain 30 eligible patients, the mean number of patients to be screened is 150.  Using the negative binomial distribution as reference, there is a 6% probability more than 190 subjects will need to be screened to attain the 30 eligible patients.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 18 (94)  The primary endpoint is the objective response rate to the combined therapy and will be assessed 
in a Simon’s two -stage optimal design. Published, historical records anticipate a response rate of 
5% or lower and we will assume a null hypothesis of 5%. We will reject this null hypothesis in favor of a higher rate if we obs erve 4 or more responses in the evaluable patient sample of 30. 
The trial will terminate early if we do not observe 1 or more responses in the first 9 evaluable patients. The probability of 4 or more responses in a sample of 30 is .049, which is the signif icance level. If the true, underlying response rate is 25% or greater, then this trial has a 
power of 90%. The expected sample size is 17 under the null hypothesis. There is a 63% chance of stopping early under the null hypothesis.  
Secondary endpoints incl ude overall survival, progression- free survival and toxicity. Survival 
endpoints  will be plotted using the Kaplan -Meier, product -limit method and compared across 
clinical measurements using Cox proportional hazards regression. Time to progression begins at  
the time of initial treatment and ends at the earliest of withdrawal, diagnosed progression, or death. Toxicity rates will be compared to established rates for these treatments and summarized using means and 95% confidence intervals. Genetic markers will be plotted using heat -maps and 
statistically compared across responders and nonresponders using the Benjamini -Hochberg 
correction for multiplicity of p -values.  
1.3 Schema  
The general study design is summarised in Figure 1. 
  
Figure 1  Study design  
 

Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 19 (94)  2. INTRODUCTION 
Colon cancer is the third most common cancer in the United States, and it accounts for 9% of all 
cancer related deaths (Cronin, Lake et al. 2018) . More than 100,000 new colon cancer cases are 
expected to be diagnosed in 2019, with about 20% of these cases having metastatic disease at 
presentation (Muratore, Zorzi et al. 2007) . Unfortunately, only a small numbe r of patients with 
stage IV disease can be cured with multimodality therapy. Hence, systemic medical therapy is essential in management of these patients. Over the last two decades a number of available systemic treatments for colon cancer have increased s ignificantly. They have improved both 
quality of life and overall survival, which now exceeds 2 years for stage IV disease (Loupakis, Cremolini e t al. 2014) .These treatments include conventional chemother apy agents 
(fluoropyrimidines, ox aliplatin, and irinotecan), angiogenesis inhibitors (bevacizumab and 
aflibercept), and anti -EGFR antibodies (cetuximab and panitumumab). Treatments such as 
regor afenib and lonsurf have had  more modest survival benefits when compared to placebo in 
the third line setting. However, the optimal sequence for the use of the available drugs is not 
clear. It is the exposure of all of the active agents that seem to be more important than the order 
of administration. Hence, the more lines of therapy we can offer to patients, the more benefit patients can derive in terms of their survival  and quality of life. Development of alternative/novel 
treatment options is essential for  our ability to treat this disease more effectively.  
Olaparib (AZD2281, KU -0059436) is a potent Polyadenosine 5’diphosphoribose [poly (ADP 
ribose)] polymerisation (PARP) inhibitor (PARP -1, -2 and - 3) that is being developed as an oral 
therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti -cancer agents.  
PARP inhibition is a novel approach to targeting tumours with deficiencies in DNA repair 
mechanisms.  PARP enzymes are essential for repairing DNA single strand breaks (SSBs).  
Inhibiting PARPs leads to the persistence of SSBs, which are then converted to the more serious 
DNA double strand breaks (DSBs) during the process of DNA replication.  During the process of 
cell division, DSBs can be efficiently repaired in normal cells by homologous recombination 
repair (HR).  Tumours with HR deficiencies (HRD), such as ovarian cancers in patients with BRCA1/2 mutations, cannot accurately repair the DNA damage, which may become lethal to 
cells as it accumulates.  In such tumour types, olaparib may offer a potentially efficacious and 
less toxic cancer treatment compared with currently available chemotherapy regimens.  
BRCA1 and BRCA2 defective tumours are intrinsically sensitive to PARP inhibitors, both in 
tumour models in vivo (Rottenberg et al 2008, Hay et al 2009) and in the clinic (Fong et al 
2009). The mechanism of action for olaparib results from the trapping of inactive PARP onto the single -strand breaks preventing their repair (Helleday 2011; Murai et al 20 12).  Persistence of 
SSBs during DNA replication results in their conversion into the more serious DNA DSBs that would normally be repaired by HR repair.  Olaparib has been shown to inhibit selected tumour cell lines in vitro and in xenograft and primary e xplant models as well as in genetic BRCA 
knock- out models, either as a stand- alone treatment or in combination with established 
chemotherapies.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 20 (94)  Temozolomide  (TMZ)  is a monofunctional alkylator of DNA  
approved for the treatment of glioblastoma multiforme  
(GBM)  and neuroendocrine tumors . Aklylation (methyl ation) 
of DNA occurs predominantly at the O6 and N1 position of 
guanine. The MGMT protein is critical for the rem oval of 06-
methylguanine lesions, which are extremely toxic in 
replicating  cells. The gene is frequently silenced by promoter 
hypermethylation in many cancers, either focally or as a result of  the CPG island methylator phenotype  (CIMP ), 
leading to TMZ  sens itivity. Three common types of 
alkylation DNA damage and their associated DNA rep air 
pathways are shown in Fig. 2, which are briefly reviewed here. The MGMT protein is critical for the removal of 06- methylguanine lesions, which are extremely toxic in repli cating cells. This 
gene is frequently silenced by promoter hypermethylation in many cancers, either focally or as a result of the CPG island methylator phenotype (CIMP), leading to TMZ  sensitivity, which is 
further discussed below. The N7- methylguanine and N3 -methyladenine lesions are repaired by 
base excision repair (BER), which is blocked by treatment with PARP inhibitors. 
2.1 Study rationale  
2.2 Background  
A detailed description of the chemistry, pharmacology, efficacy, and safety of  olaparib  is 
provided in the  investigator’s brochure, and for temozolomide, the package insert.   
O6-Methylguanine DNA Methyltransferase and Cpg Island Methylator Phenotype in 
Gastrointestinal Malignancies: Dysregulation of DNA repair plays a major role in the initiation 
and progress ion for a variety of gastrointestinal (GI) malignancies. This can range from BRCA 
mutations seen in pancreatic cancer, oncometabolite formation seen in isocitrate dehydrogenase 
(IDH) mutant cholangiocarcinoma or O6-methylguanine DNA methyltransferase (MGMT ) 
promoter hypermethylation in colorectal, neuroendocrine, and gastroesophageal cancers. 
Temozolomide (TMZ) has shown activity in many of these malignancies in the relapsed / 
refractory setting; however the duration of benefit has been modest. Based on TMZ  resistance 
mechanisms described below, preliminary data suggests the addition of PARP inhibitors can lead 
to a sustained anti -tumor response. We thus propose a biomarker driven, open- label clinical trial 
with TMZ in combination with the poly ADP ribose polymerase (PARP) inhibitor olaparib.  
Promoter hypermethylation of MGMT is most widely described in glioma where it can be seen together with IDH mutations in grades 2 and 3 glioma, or spontaneously in grade 4. IDH mutant 
gliomas are accompanied by CIMP , which almost universally results in MGMT promoter 
methylation in these tumors (Noushmehr 2010, Turcan 2012, van den Bent 2013, Clark 2016) . 
Promoter hypermethylation ultimately causes decreased MGMT expression and renders these tumors more susceptible to TMZ (Hegi 2005, Brandes 2006, Chinot 2007) . Both  reductions in 
MGMT expression and MGMT promoter hypermethylation are described in a variety of 
gastrointestinal malignancies.  This includes up to 40% of colorectal adenocarcinoma as well as 
subsets of gastric, pancreatic, and neuroendocrine tumors where it has been associated with increased sensitivity to TMZ and dacarbazine (Esteller 1999, Bae 2002, Konduri 2009, Kulke 
Fig. 2.  Overview of three key alkylation 
damage repair pathways.  

Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 21 (94)  2009, Walter 2015, Thomas 2017) . Additionally, m utations in  IDH create the oncometabolite 2 -
hydroxyglutarate (2HG), which creates CIMP, and ultimately leads to MGMT promoter 
hypermethylation. In cholangiocarcinoma IDH mutations occur in up to 15- 20% of cases 
(Borger, Ta nabe et al. 2012, Javle, Bekaii Saab et al. 2016) . 
The monofunctional alkylator, TMZ causes three common types of alkylation DNA damage  (Fig 
1.). The MGMT protein is the major pathway  for the removal of 06 -methylguanine lesions, 
which are extremely toxic in replicating cells  and is fre quently silenced by promoter 
hypermethylation in many cancers, either focally or as a result of CIMP, which may be IDH1/2 induced, leading to TMZ sensitivity, which is further discussed below. The ALKBH -2 and - 3 
proteins repair N1- methyladenine and N3 -meth ylcytosine lesions, and they are both inhibited by 
the oncometabolite 2HG, leading to TMZ sensitivity  in this subset  (Wang, Wu et al. 2015, Chen, 
Bian et al. 2017) . Finally, N7- methylguanine and N3 -methyladenine lesions are repaired by base 
excision repair , which is blocked by treatment with PARP inhibitors. Collectively, these findings 
suggest that gastrointestinal tumors with MGMT promoter silencing and/or IDH1/2 mutations will be sensitive to TMZ -based therapeutics.  
In colorectal  cancer CIMP is well described, which can be caused by a variety of epigenetic 
changes , including the oncometeabolite 2HG  (Figueroa 2010, Noushmehr 2010, Curtin, Slattery 
et al. 2011, Turcan 2012, Hughes, Melotte et al. 2013, van den Bent 2013) . In glioma, CIMP 
status is associated with a better prognosis (Ceccarelli, Barthel et al. 2016) , while 
oncometabolite -driven CIMP in SDH mutant tumors seems to be associated with a worse 
prognosis (Letouze, Martinelli et al. 2013) . The promoter of MGMT is frequently silenced in 
CIMP -positive tumors (van den Bent 2013) . As discussed below, MGMT promoter 
hypermethylation predicts for sensitivity to alkylators, such as TMZ, and thus it is an important 
prognostic factor (Hegi 2005, Brandes 2006, Chinot 2007) . The  CIMP also drives ARID1A 
promoter silencing, which encodes a gene important for the replication fork stability. Loss of 
ARID1A was recently shown to confer sensitivity to both ATR and PARP inhibitors (Shen, Peng 
et al. 2015, Williamson, Miller et al. 2016) , and these mutations are well described in a multitude 
of cancers including pancreatic cancer (Ryan 2014) .  
Temozolomide and PARP inhibitors: The combination of TMZ with PARP inhibi tors has also 
gained traction with multiple ongoing clinical trials evaluating various combination in multiple diseases ([STUDY_ID_REMOVED], NCT0215982, [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED] and 
others) (Ohmoto and Yachida 2017) . Inhibitors of base excision repair  and MGMT have been 
shown to  sensitize tumors to TMZ (Delaney 2000, Liu, Yan et al. 2003, Barvaux 2004, Luo 
2004, Trivedi 2005, Hermisson 2006, Yan, Bulgar et al. 2007) . Tumor sensitivity to TMZ is 
increased in combination with PARP inhibitors in cell lines and xenografts both in  vitro  and in  
vivo (Delaney 2000, Tentori, Portarena et al. 2001, Tentori, Portarena et al. 2001, Tentori, 
Leonetti et al. 2003, Calabrese, Almassy et al. 2004, Curtin, Wang et al. 2004, Jagtap and Szabó 2005, Pa lma, Wang et al. 2009, Gill, Travers et al. 2015, Smith, Reynolds et al. 2015) . 
Furthermore, the PARP inhibitor, veliparib, reverses TMZ resistance in multiple xenografts of 
various tumor types (Palma, Wang et al. 2009) . As stated above the base excision repair  pathway 
is an important pathway for demethylation; however , the increased TMZ sensitivity with PARP 
inhibitors is likely multifactorial (Boulton, Pemberton et al. 1995, Jagtap and Szabó 2005) . For 
example, stalled replication forks are typically overcome by HR DNA repair, but PA RP 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 22 (94)  inhibitors can delay the initiation of this HR -mediated recovery (Yang, Cortes et al. 2004, 
Cimprich and Cort ez 2008, Lavin 2008) . In addition, PARP trapping appears to be critical for 
improving TMZ sensitivity, which makes olaparib an ideal PARP inhibitor to use in combination 
with TMZ (Murai, Huang et al. 2012, Murai, Zhang et al. 2014, Pommier, O’Connor et al. 2016) .  
Multiple dose levels and schedules for olapa rib and TMZ have been evaluated in GBM and small 
cell lung cancer. In  small cell carcinoma intermittent dosing (days 1 -7) of o laparib 200 mg twice 
daily and TMZ 75 mg/m2 every 21 days was reported to be safe with observed clinical activity 
(Farago, Drapkin et al. 2 018). Here we propose continuous dosing of olaparib 150 mg twice 
daily  with TMZ 75 mg/m2 days, which is further outlined in section 4.3 “Justification for dose.”  
Temozolomide in Advanced Colorectal Cancer (CRC): Recent phase II studies evaluating 
MGMT m ethylated CRC revealed an average response rate of 10% in chemo -refractory disease 
treated with dacarbazine or TMZ  monotherapy  (Amatu, Sartore -Bianchi et al. 2013, Hochhauser, 
Glynne -Jones et al. 2 013, Pietrantonio, Perrone et al. 2014, Amatu, Barault et al. 2016, 
Pietrantonio, de Braud et al. 2016, Calegari, Inno et al. 2017) . As noted above, methylation of 
MGMT and/or decreased MGMT expression is seen in up to 40% of CRC (Esteller 1999, Esteller and Herman 2004, Suehiro, Wong et al. 2008, Shacham -Shmueli, Beny et al. 2011, 
Thomas 2017, Morano, Corallo et al. 2018) . Notably, MGMT prom oter hypermethylation is 
even more common in CRC with KRAS G>A mutations, which may be a result of promoter methylation causing somatic KRAS mutations (E steller, Toyota et al. 2000, Shacham -Shmueli, 
Beny et al. 2011) . Moreover, a small phase II study evaluated veliparib and TMZ in advanced 
CRC met its primary endpoint with a 24% disease c ontrol rate after 2 cycles (Pishvaian , Slack et 
al.). Interestingly, PTEN expression and MGMT expression were not predictors of benefit 
although the sample size was limited. These findings are despite veliparib being poor at PARP trapping, and more significant TMZ sensitization may be seen with other PARP inhibitors such 
as olaparib (Murai, Huang et al. 2012, Murai, Zhang et al. 2014, Pommier, O’Connor et al. 
2016) . Temozolomide combinations in CRC continue to be explored, and our collaborators at the 
Italian National Cancer Institute recently demonstrated in two subsequent single -institutional 
single arm trials good tolerability  and encouraging clinical activity of TMZ in chemorefractory 
CRC patients with MGMT  silencing, even in the RAS -BRAF -mutated population. They also 
evaluated the prognostic and predictive value of  MGMT immunohistochemistry and of 
MGMT  methylation testing both in tumor and cell- free c irculating DNA with an ultra -sensitive 
two-step digital PCR technique (methyl -BEAMing) (Barault 2015, Sartore -Bianchi, Pietrantonio 
et al. 2017) . Their recent investigator i nitiated clinical trial published May 2018 in Annals of 
Oncology revealed a 24% ORR with the combination of TMZ and irinotecan for refractory 
MGMT methylated CRC  (Morano, Corallo et  al. 2018) . Notably, all the responders were MGMT 
negative by IHC and these patients were noted to have a significantly longer PFS.  
As noted above, an intact MMR pathway is needed for TMZ sensitivity, and sporadic loss of this pathway has been described as a mechanism of resistance to TMZ (Nagel, Kitange et al. 2017, 
Thomas, Tanaka et al. 2017) . While MMR deficiency may result in resistance to TMZ based 
therapies, it’s be en shown to stimulate neoantigen production and confer dramatic sensitivity to 
anti-PD-1 therapies (Le, Uram et al. 2015, Le, Durham et al. 2017) . Thus responding patients 
may acquire MMR deficiency at progression and an on- progression biopsy for TMZ based 
therapies can be used to assess for the benefit of immune checkpoint t herapy.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 23 (94)  Based on the above rationale we propose to evaluate the safety and efficacy of the TMZ + 
olaparib combination in colorectal adenocarcinoma with MGMT promoter hypermethylation.  
2.3 Benefit/risk a ssessment  
More detailed information about the known and e xpected benefits and risks and reasonably 
expected AEs of olaparib may be found in the IB, and for temozolomide in the package insert.  
2.3.1 Potential benefits  and risks for olaparib  
Approximately 15% of ovarian cancer patients and 5% of breast, pancreatic and prostate cancer 
patients have inherited mutations of BRCA1 or BRCA2. In addition to genetic loss of BRCA function, it has been suggested that a further ~20% of tumours display so -called “BRCAness” 
(Narod and Foulkes 2004; Chan et al 2002). Furthermore, reduced function of other key proteins in the homologous recombination pathway similarly results in increased sensitivity to PARP inhibition and enhancement of chemotherapy and radi otherapy treatments. For these reasons, 
PARP inhibition represents a novel approach to anti -tumour therapy and may address an unmet 
need in patients with BRCA associated cancer. In addition, the use of PARP inhibitors in combination has confirmed that an e nhancement of the anti -tumour activity of radiation and 
DNA damaging cytotoxic agents occurs (Virag and Szabo 2002, Nguewa et al 2005). Identification of safe and effective doses of olaparib in combination regimens offers potential in many tumour types.  
 As of 15 December 2018 , approximately 10682 patients are estimated to have received olaparib 
in the clinical programme including AstraZeneca -sponsored studies ( 6108 patients), a MAP ( 848 
patients), ISSs and collaborative group studies ( 3726 patients). An e stimated 6956 patients with 
ovarian, breast, pancreatic, gastric and a variety of other solid tumours are estimated to have received treatment with olaparib in AstraZeneca -sponsored, interventional studies ( 6108 
patients) and the MAP ( 848 patients). Since 2012/2013, most new clinical studies have utilised 
the tablet formulation, which was designed to deliver the therapeutic dose of olaparib in fewer dose units than the capsule. Of the 6108 patients in AstraZeneca -sponsored, interventional 
studies, 1512 rece ived the capsule formulation, 4516 received the tablet formulation, and 25 
received both capsule and tablet. In the AstraZeneca- sponsored, interventional studies, olaparib 
was given either as monotherapy ( 4350 patients) or in combination with chemotherapy or other 
anti-cancer agents, including studies where patients received monotherapy and combination 
therapy sequentially (n=1758).  Approximately 2071 patients have received comparator or 
placebo across the olaparib development programme in AstraZeneca -spons ored studies.  
 Data from the available pre- clinical studies and subsequent clinical development programme 
demonstrate that olaparib appears to be active and generally well tolerated in patients with solid 
tumors  including those with BRCA mutated cancers. In ovarian cancer, responses have been seen 
in all patient groups, including platinum resistant and refractory cancer.  
From the available data to date in patients with advanced cancer, there is no evidence of any unexpected toxicity following long -term olaparib (capsule) monotherapy exposure.  
Adverse laboratory findings and/or clinical diagnoses considered to be causally associated with administration of olaparib monotherapy include haematological effects (anaemia, neutropenia, lymphopenia, thrombocytopenia, MCV elevation and increase in blood creatinine), nausea and vomiting, decreased appetite, diarrhea, dyspepsia, stomatitis, upper abdominal pain, dysgeusia, 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 24 (94)  fatigue (including asthenia), headache, dizziness and cough. Most of these events were generally  
mild or moderate in intensity.  
 
In a relatively small number of patients, pneumonitis, MDS/AML and new primary malignancies 
have been observed. Evidence from across the development programme for olaparib does not 
support a conclusion that there is a caus al relationship between olaparib and these events. These 
are important potential risks for olaparib and are being kept under close surveillance.  
Data from studies of olaparib in combination with various chemotherapy agents indicate an increase in bone marr ow toxicity (anaemia, neutropenia, thrombocytopenia) greater than 
expected if the agents had been administered alone. The effects are generally transient but 
treatment delays are common and alternative administration schedules/toxicity management 
processes  are currently being evaluated within some of these studies. When this type of toxicity 
has occurred it has been managed by routine clinical practice including dose delays, dose 
reductions, intermittent dosing and/or the use of supportive care measures, including G -CSF. 
Currently, all ongoing olaparib combination studies are being closely monitored for 
myelotoxicity. Results of a Phase II study in combination with carboplatin/paclitaxel (Study 
D0810C00041) showed that addition of olaparib to carboplatin AUC  4 + paclitaxel in the 
chemotherapy phase had a generally similar tolerability profile to carboplatin AUC 6 + 
paclitaxel. The regimen of olaparib capsules 200 mg bd for 10 days out of 21, with carboplatin 
AUC 4 + paclitaxel had an acceptable and manageable tolerability profile in patients with 
recurrent serous ovarian cancer. Olaparib tolerability during the monotherapy maintenance phase was consistent with the previously known safety and tolerability profile. In Study D0810C00039 
and Study D081BC00004, ola parib 100 mg tablet bd in combination with weekly paclitaxel 80 
mg/m2 was well tolerated, with no new unexpected safety findings. In both studies, the incidence 
of neutropenia was higher for the olaparib combination arm and this contributed to higher rates  
of dose modifications for patients on olaparib compared to placebo. In Study D081BC00004, 
there was also a higher incidence of anaemia on the olaparib + paclitaxel combination arm than on the placebo + paclitaxel arm and more dose interruptions, reductions and discontinuations. 
2.3.2 Potential benefits and risks for temozolomide  
Risks with temozolomide include, but are not limited to, thrombocytopenia, nausea, vomiting, 
anorexia, constipation alopecia, headache, and constipation.  
For more information on all ide ntified and potential risks with temozolomide, please always refer 
to the package insert.  
In adult monotherapy clinical studies, AEs (all grades) reported very commonly (≥10% of patients) are anorexia, fatigue, headache, convulsions, constipation, diarrhea, nausea, vomiting, 
alopecia,  and rash. In a single arm anaplastic astrocytoma trial, hemiparesis, dizziness, abnormal 
coordination, amnesia, insomnia, and viral infections were also reported very commonly, however, in the absence of a control group it is not clear in many cases whether these reactions should be attributed to temozolomide or the patients’ underlying condition. 
Temozolomide monotherapy is typically used at a dose of 150- 200 mg/m2 on days 1 -5 of every 
21 or 28 day cycles. It is also used in combination with radiation, and is currently being 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 25 (94)  investigated in combination with novel agents in multiple prospective clinical trials, including 
with PARP inhibitors. Temozolomide has been combined with olaparib in multiple clinical trials 
and ha s been deemed safe and worthy of further evaluation in both GBM and small cell lung 
cancer (Fulton, Short et al. 2017, Halford, Cruickshank et al. 2017, Farago, Drapkin et al. 2018) . 
Objective radiographic responses have been observed and multiple dosing schemes are currently being evaluated. Intermittent dosing of olaparib 200 mg t wice daily days 1 -5 or 1 -7 with 
temozolomide 75 mg/m2 days 1 -5 or 1 -7 has already been evaluated and deemed safe (Fulton, 
Short et al. 2017, Farago, Drapkin et al. 2018) . Similarly, the OPARATIC trial concluded 
continuous TMZ 75 mg/m2 and olaparib 150 mg days 1 -3 weekly was a safe dose for 
expansion(Halford, Cruickshank et al. 2017) . Given the need for continuous PARP inhibition, 
PARP inhibition with olaparib 150 mg twice daily in combination with intermittent temozolomide 50- 75 mg/m2 is being studied for small cell lung  cancer by Farago et al, which is 
further detailed in section 4.3 Justification for dose .  
2.3.3         Overall benefit/risk  
      The treatment options cur rently available for CRC patients after 5 -fluoruracil, 
oxaliplatin, and irinotecan remain limited. Current standard therapy of TAS -102 or regorafenib is  
likely to result in modest improvements in long -term survival, and additional and alternative 
therapies are required for patient s with refractory colorectal cancer. Therefore, there remains an 
unmet medical need for this patient population. The molecular targeting of olaparib to specific 
subsets of tumors may provide an opportunity for more effective and potentially less toxic canc er 
treatment for some patients compared with currently available regimens.  
3. OBJECTIVES AND ENDPO INTS  
Hypothesis:  We hypothesize that MGMT promoter hypermethylation will sensitize tumors  to 
the combination of t emozolomide with the PARP inhibitor olaparib. 
Primary Objectives:  
• To determine the efficacy of TMZ in combination with olaparib as measured by 
the overall response rate.  
 
Secondary Objectives:  
• To determine the safety of TMZ in combination with olaparib. 
• To estimate progression free survival (PFS).  
• To estimate overall survival (OS).  
 
Exploratory Objectives:  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 26 (94)  • Identify patterns of next generation sequencing analysis, DNA methylation, 
mutational load and gene expression in MGMT promoter hypermethylated colorectal cancer.  
• Correlate molecular features with markers of DNA damage including γ H2AX 
phosphorylation levels.  
• Establish organoids for MGMT promoter hypermethylated colorectal cancer.  
 
Primary Endpoints:  
• Objective response rate by RECIST v1.1 criteria for combined therapy with temozolomide and olaparib.  
Secondary Endpoints:  
• Progression free survival. 
• Overall survival.  
• Rate of ≥  grade 3 adverse events.  
 
Exploratory Endpoints:  
• Association of NGS profiling, patterns of DNA  methylation, gene expression, and 
develop MGMT expression assays with efficacy and clinical parameters.  
• Association of γ H2AX with response rate and survival endpoints. 
• Form a library of colorectal cancer organoids  
4. STUDY DESIGN 
4.1 Overall design  
This is an open -label single arm study of olaparib + temozolomide for MGMT promoter 
hypermethylated CRC. Potentially eligible patients will be tested for MGMT promoter 
hypermethylation by methylation specific PCR after signing a pre -screening consent. If patients 
screen positive for MGMT promoter hypermethylation they will potentially be eligible for 
enrollment. The study will begin with a safety evaluation period as outlined in section 4.2 to 
assess tolerability of olaparib and TMZ in the study population. Throughout t he study patients 
will continue with olaparib and temozolomide until objective disease progression (determined by 
RECIST  v1.1) as long as in th e investigator’s opinion they are benefiting from treatment and 
they do not meet any other discontinuation criter ia. 
Once patients have been discontinued from study treatment, other treatment options will be at the discretion of the investigator.  
For an overview of the study design see Figure 1, Section 1.3. For details on treatments given 
during the study, see Section 6.1 Treatments Administered.    
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 27 (94)  For details on what is included in the efficacy and safety endpoints, see Section 3 Objectives and 
Endpoints.   As detailed in the consent form, patients will be asked for authorization to send 
DNA samples  to the National Institutes of Health (NIH) Database of Genotypes and Phenotypes 
(dbGaP) bank (or other NIH -funded database if indicated) where it can be used for future 
research projects as necessitated by funding agency regulations. All information will be de -
identified prior to submission to the NIH dbGaP database (or other NIH -funded database if 
indicated).  
 
4.2 Safety Evaluation Period  
A safety evaluation period to assess for dose limiting toxicity (DLT) will be employed for at 
least the first 6 treated p atients. Should excessive toxicity be observed at the starting dose , a dose 
de-escalation schema will be used for TMZ to 60 mg/m2, while the  olaparib  will be maintained at 
the specified dose  of 150 mg twice daily . Patients will be enrolled in cohorts of 3 during the 
safety evaluation period. For the first 3 patients treated on the study with olaparib 150 mg twice 
daily and TMZ 75 mg/m2, if ≤1/3 DLTs are observed, 3 additional patients will be enrolled at 
this dose  and if ≤1/6 DLTs are seen enrolment will pr oceed at this dose. If 2 or more DLTs are 
observed in either the first 3 or 6 patients treated at the starting doses , the TMZ  dose will be 
decreased to 60 mg/m2 with olaparib 150 mg twice daily. If 2 or more DLTS are seen in either 
the first 3 or 6 patient s treated at TMZ 6 0 mg/m2 with olaparib 150 mg twice daily then a further 
dose reduction to TMZ 50 mg/m2 with olaparib 150 mg twice daily will be done. The doses of 
TMZ 50 mg/m2 D1-7 with olaparib 150 mg twice daily have previously been tested as outlined 
in section 4.5. Therefore if the starting doses require reduction to TMZ 50 mg/m2 D1-7 with 
olaparib 150 mg twice daily then safety will be assessed per the data safety monitoring plan as 
outlined in section 9.5.2.  
The dose management tables throughout the protocol will be adjusted in an amendment as 
necessary if an alternate starting dose is identified. If a dose reduction is necessary, at least 9 
patients (per early stopping rule) and up to 30 evaluable patients will be treated at the reduced 
dose as par t of the efficacy analysis. Therefore in the case of a dose reduction the enrolment of 
30 patients will be maintained at the same dose.  
 
4.3 Dose Limiting Toxicity Definition  
Dose limiting toxicities will be determined on events that occu r during the first 21 -day cycle for 
patients in the safety evaluation period. 
Any adverse event of Grade 3 or higher that is at least “possibly related” to olaparib  or TMZ  will 
be considered a DLT, unless there is a clear alternative explanation as to the cause of the AE 
(e.g., disease related), as well as  the following  conditions : 
• Delays of  > 7 consecutive days that occurs as a result of TMZ or olaparib.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 28 (94)  • Grade 3 mucositis, nausea, vomiting, or diarrhea, AST/ALT elevation will only be 
considered a DLT if it lasts more than 72 hours despite optimal supportive care.  
• Grade 4 mucositis, nausea, vomiting, and diarrhea will be considered DLTs if they reach grade 4 severity despite optimal supportive care, irrespective of duration.  
• Any grade 4 hematologic toxicity with the following e xceptions:  
o Grade 4 neutropenia will only be considered a DLT if it lasts ≥ 7 days  
• Any febrile neutropenia will be considered a DLT.  
• Any adverse event that meets the definition of Hy’s Law.  
• Hypersensitivity/Infusion reactions will not be considered a DLT ( hypersensitivity 
reactions are generally not related to the dose level of the drug since they can occur even  
Subje cts who do not complete both 75% of the TMZ and 75% of the olaparib  doses in the 21- day 
DLT evaluation period, due to reasons other than occurrence of DLT(s) will be considered non-
evaluable for DLT, and may be replaced to ensure the accrual of the minimum number of subjects to adequately assess tolerability as outlined in the safety evaluation period.  
4.4 Scientific rationale for study d esign  
4.5 Justification for d ose 
The approved monotherapy dose of olaparib is 300 mg twice daily for the tablet formulation 
(Olaparib IB). However, when used in combination with additional systemic therapies the 
olaparib dose is often reduced (Olaparib IB). Temozolomide has numerous established dosage regimens pursuant to whether or not it is used in combination with additional systemic agents or 
radiotherapy (Refer to TMZ package insert). The combination of olaparib and TMZ has been 
studied in cell line and pre -clinica l rodent models. Combination studies in rats suggested 
potential for olaparib to exacerbate the effects of TMZ, or topotecan, although combination for 
olaparib with these anticancer agents did not induce any additional target organ toxicities to 
those seen  with single agent administration (Olaparib IB). Furthermore, the olaparib and TMZ 
combination is actively being investigated in humans in combination with TMZ in both small 
cell lung cancer and GBM . In GBM PARADIGM -2 is investigating various dose levels up to 
olaparib 150 mg twice daily (Days 1 -5) and TMZ 75 mg/m
2 daily (continuous) with concomitant 
radiotherapy (Fulton, Short et al. 2017) . Also in GBM the OPARATIC trial concluded 
continuous TMZ 75 mg/m2 and olaparib 150 mg days 1 -3 weekly was a safe dose for expansion 
(Halford, Cruickshank et al. 2017) . This further supports the safety of continuous dosing. While 
in small cell lung cancer a 3+3 dose escalation identified olaparib 200 mg twice daily (Days 1 -7) 
and TMZ 75 mg/m2 (Days 1 -7) as the recommend phase 2 dose of the combination (Farago, 
Drapkin et al. 2018) . However, to achieve continuous PARP inhibition and PARP trapping, 
olaparib is being investigated with continuous dosing is  being tested by Farago et al. At present 
doses of olaparib 150 mg twice daily (continuous) with TMZ  50-75 mg/m2 daily (D1 -7) are 
tolerable with no unanticipated toxicities although published data is unavailable at this time. 
Therefore, we will proceed with 21 day cycles of olaparib  150 mg twice daily ( continuous – days 
1-21) + TMZ 75 mg/m2  (days 1 -7) with a dose de -escalation schema if unacceptable toxicity is 
observed in the first 6 patients. 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 29 (94)  4.6 End of study d efinition  
The end of study is defined as the last expected visit /contact  of the last patient  undergoing the 
study.  
5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
Each patient  should meet all of the inclusion cri teria and none of the exclusion criteria for this 
study in order to assigned to a study intervention.  Under no circumstances can there be exceptions to this rule. Patient s who do not meet the entry requirements are screen failures, refer 
to section 5.4. 
5.1 Inclusion c riteria  
Patient s are eligible to be included in the study only if all the following inclusion criteria and 
none of the exclusion criteria apply:  
Informed c onsent  
1. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this 
protocol. 
2. Provision of signed and dated, written informed consent  form  prior to any mandatory 
study specific proce dures, sampling, and analyses.  
3. For inclusion in i) the optional exploratory genetic research  and ii) the optional 
biomarker research, patients must fulfi l the following criteria:  
• Provision of informed consent for genetic research prior to collection of sample  
• Provision of informed consent for biomarker research prior to collection of sample   
If a patient declines to participate in the optional exploratory genetic research or the optional 
biomarker research, there will be no penalty or loss of benefit to the patient.  The patient will not 
be excluded from other aspects of the study.  
Age 
4. Subject  must be at least 18  years of age inclusive, at the time of signing the informed 
consent  form . 
Type of patient  and disease characteristics  
5. Individuals who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring . 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 30 (94)  6. Individuals with histologically proven relapsed/refractory mismatch repair proficient / 
microsatellite stable metas tatic colorectal adenocarcinoma.  
7. MGMT promoter hypermethylation on pre -screening.  
8. Patients must have had recurrence, progression or intolerance to standard therapy 
consisting of at least 2 prior sta ndard regimens (containing a fluropyrimidine plus a 
platinum analogue and/or irinotecan) for metastatic disease. In the case where all 
chemotherapy agents are used concurrently (I.e. FOLFOXIRI +/ - Bevacizumab) 1 
prior treatment regimen is acceptable after discussion with the principal investigator. 
Relapse within 6 months of completing adjuvant chemotherapy is considered one line of therapy in the metastatic setting.  
9. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:  
• Haemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days   
• Absolute neutrophil count (ANC) ≥ 1.5 x 10
9/L 
• Platelet count ≥ 100 x 109/L 
• Total bilirubin ≤ 1.5 x institutional upper limit of norm al (ULN)  
• Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN  
• Patients must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft -
Gault equation or based on a 24 hour urine test :  
Estimated creatinine clearance =  (140- age [years]) x weight (kg)     (x F)a 
     serum creatinine (mg/dL) x 72  
a where F=0.85 for females and F=1 for males.  
10. Eastern Cooperative Oncology Group (ECOG) performance status 0- 1 (see Appendix 
D).  
11. Patients must have a life expectancy ≥ 16 weeks.  
12. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements . 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 31 (94)  Reproduct ion 
13. Postmenopausal or evidence of non- childbearing status for women of childbearing 
potential: negative urine or serum pregnancy test within 28 days of study treatment 
and confirmed prior to treatment on day 1.  
Postmenopausal is defined as:  
• Amenorr heic for 1 year or more following cessation of exogenous hormonal treatments  
• Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50  
• radiation -induced oophorectomy with last menses >1 year ago  
• chemotherapy -induced menopause with >1 year interval since last menses  
• surgical sterilisation (bilateral oophorectomy or hysterectomy)  
 
14.  Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman 
of childbearing potential.   Female partners of male patients should also use a highly 
effective form of contraception ([ see appendix C  for acceptable methods]) if they are 
of childbearing potential  
 
5.2 Exclusion  criteria  
Medical conditions  
1. Other malignancy unless curatively treated with no evidence of disease for ≥5 years 
except : adequately treated non- melanoma skin cancer, curatively treated in situ cancer 
of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial 
carcinoma.   
2. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as 
judged by the investigator  (eg., unstable ischemia, uncontrolled symptomatic 
arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte 
disturbances, etc.), or patients with congenital long QT syndrome . 
3. Persistent toxicities ( Common Terminology Criteria for Adverse Event  (CTCAE) 
grade 2) caused by previous cancer therapy, excluding alopecia.  
4. Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML. 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 32 (94)  5. Patients with symptomatic uncontrolled brain metastases.  A scan to  confirm the 
absence of brain metastases is not required. The patient can receive a stable dose of 
corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.  Patients with spinal cord compression unless considered to 
have received definitive treatment for this and evidence of clinically stable disease for 
28 days.  
6. Patients considered a poor medical risk due to a serious, uncontrolled medical 
disorder, non- malignant systemic disease or active, uncontrolled  infection.  Examples 
include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 
months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal 
cord compression, superior vena cava syndrome, extensive inters titial bilateral lung 
disease on High Resolution Computed Tomography  (HRCT) scan or any psychiatric 
disorder that prohibits obtaining informed consent. 
7. Patients unable to swallow orally administered medication and patients with 
gastrointestinal disorders likely to interfere with absorption of the study medication.  
8. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV). 
9. Patients with known active hepatitis (i.e. Hepatitis B or C).   
− Active  hepatitis B virus (HBV) is defined by a known positive HBV surface 
antigen (HBsAg) result.  Patient s with a past or resolved HBV infection (defined 
as the presence of hepatitis B core antibody and absence of HBsAg) are eligible.  
− Patient s positive for hepa titis C virus (HCV) antibody are eligible only if 
polymerase chain reaction is negative for HCV RNA.  
Prior/concomitant t herapy  
10. Any previous treatment with PARP inhibitor, including Olaparib.  
11. Any previous treatment with temozolomide or other monofunctional alkylating agent.  
12. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment  
13. Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, prot ease inhibitors boosted with ritonavir or cobicistat, indinavir, 
saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. 
ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout 
period prior to startin g olaparib and temozolomide  is 2 weeks.  
14. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, 
rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s Wort  ) or 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 33 (94)  moderate CYP3A  inducers (eg. bosentan, efavirenz, modafinil ). The required washout 
period prior to starting olaparib and temozolomide  is 5 weeks for enzalutamide or 
phenobarbital and 3 weeks for other agents.  
15. Major surgery within 2 weeks of starting study treatment and patients must have 
recovered from an y effects of any major surgery.  
16. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). 
17. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions ar e acceptable, for timing refer to inclusion 
criteria no. 8). 
Prior/ concurrent clinical study experience  
18. Participation in another clinical study with an investigational product administered in the last 28 days.  
19. Subject s with a known hypersensitivity to temoz olomide , olaparib, any of the 
excipients of either  product , or the combination.  
20. Patients with a known hypersensitivity to the  combination/comparator agent. 
Other exclusions  
21. Involvement in the planning and/or conduct of the study  
22. Judgment by the investigator that the patient  should not participate in the study if the 
patient  is unlikely to comply with study procedures, restrictions and requirements. 
23. Previous enrolment  in the present study .  
24. Breast feeding women.  
5.3 Lifestyle restrict ions 
5.3.1 Meals an d dietary restrictions  
It is prohibited to consume grapefruit juice while on temozolomide and olaparib therapy.  
5.3.2 Activity  
Contraception  
Women of childbearing potential and their partners, who are sexually active, must agree to the 
use of TWO highly effective forms of contraception in combination (as described in Appendix  
C).  This should be  started  from the signing of the informed  consent and continue throughout the 
period of taking study treatment  and for at least 6 months  after last dose of study drug(s), or they 
must totally/truly abstain from any form of sexual interco urse (as described in Appendix C ). 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 34 (94)  Male patients must use a condom during treatment and for 3 months after the last dose of 
olaparib when having sexual intercourse with a preg nant woman or with a woman of 
childbearing potential.   Female partners of male patients should also use a highly effective form 
of contracep tion (as described in Appendix C ) if they are of childbearing potential.  Male 
patients should not donate sperm throughout the period of taking olaparib and for 3 months 
following the last dose of olaparib.  
For details of acceptable methods of c ontraception refer to Appendix C  Acceptable Birth Control 
Methods. 
5.4 Screen f ailures  
Screen failures are defined as patient s who signed the informed consent form to participate in the 
clinical study  but are not subsequently  entered in the study  due to not meeting eligibility criteria . 
Patients who decide they no longer want to participate in the study either in screening or before 
completing 1 cycle of therapy will be considered a withdrawal.  Minimal information includes 
demography, screen failure details, eligibility criteria, and any serious adverse event  (SAE).  
Individuals who do not meet the criteria for participation in this study (screen failure) may  be 
rescreened  up to 2 times .   
These patient s should have the reason for study withdrawal recorded in the e CRF . 
6. STUDY TREATMENT S 
Study treatment  is defined as any  investigational product(s) (including marketed product 
comparator and placebo) or medical device(s) intended to be administered to a study participant according to the study protocol. Study treatment  in this study refers to olaparib and 
temozolomide.  If excessive DLTs are observed at the starting doses for the investigational 
products, alternate dos es are outlined in section 4.2. 
6.1 Treatment s administered  
6.1.1 Investigational p roducts  
 
Table 2 Study Treatments   
 olaparib  Temozolomide   
Study treatment name:  
 Olaparib  Temozolomide   
Dosage formulation:  150 mg twice daily  75 mg/m2 days 1 -7  
    
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 35 (94)  Route of administration  Oral Oral  
Dosing instructions:  
 Olaparib tablets 
should be taken at 
the same time each 
day, approximately 
12 hours apart  (±3 
hours)  with one 
glass of water.  The 
tablets should be 
swallowed whole 
and not chewed, 
crushed, dissolved or 
divided. Olaparib  
tablets can be taken with or without 
food.  Temozolomide 
tablets should be 
taken at the same 
time as the AM 
olaparib dose.   
Packaging and labelling  
 Olaparib will be 
supplied from 
commercial stock. 
Study treatment will 
be provided. Each  
container  will be 
labelled in 
accordance with 
Good Manufacturing 
Practice (GMP) 
Annex 13 and per country regulatory 
requirement.    
 
If vomiting occur s shortly after the olaparib tablets are swallowed, the dose should only be 
replaced if all of the intact tablets can be seen and counted.  Should any patient enrolled on the 
study miss a scheduled dose for whatever reason (e.g., as a result  of forgetting to take the tablets 
or vomiting), the patient will be allowed to take the scheduled dose up to a maximum of 2 hours 
after that scheduled dose time.  If greater than 2 hours after the scheduled dose time, the missed 
dose is not to be taken an d the patient should take their allotted dose at the next scheduled time. 
6.2 Preparation/handling/storage/accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment  received and any discrepancies are reported and 
resolved before use of the study treatment . 
Only patient s enrolled  in the study may receive study treatment and only author ised site staff 
may dispense  study treatment .  At site,  all study treatment s must be s tored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the labelled  storage conditions with access limited to the investigator and author ised site staff.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 36 (94)  The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance ( i.e., 
receipt, reconciliation, and final disposition records). 
Further guidance and information for the final disposition of unused study treatment  are provided 
in the pharmacy manual.    
6.3 Measures to minimise bias: randomisation and blinding  
This is an open- label single arm clinical trial and therefore there is no ra ndomisation or blinding. 
If a patient  withdraws from th e study, then his/her enrolment  code cannot be reused.  Withdrawn 
patient s will not be replaced provided they have completed at least 1 cycle of therapy.  
6.4 Treatment  compliance   
Patients should be given clear instructions on how and when to take their study treatment.  
Patients will self -administer olaparib and temozolomide .   Study site staff will count tablet s at 
regular intervals during treatment.  After the tablet count has been performed, the remaini ng 
tablets will not be returned to the patient but will be retained by the investigative site.  All 
patients must return their bottle(s) of olaparib and temozolomide at the appropriate scheduled 
visit, when a new bottle will be dispensed. Patients will be instructed to notify study site personnel of missed doses.   
Any change from the dosing schedule, does interruptions, dose reductions, dose discontinuations 
should be recorded in eCRF. 
The Investigational Product Storage Manager is responsible for managing the IMP from receipt 
by the study site until the destruction or return of all unused IMP.  The Investigator(s) is 
responsible for ensuring that the patient  has returned all unused IMP. 
 
6.5 Concomitant therapy  
The use of any natural/herbal products or other traditional remedies should be discouraged, but 
use of these products, as well as a ny medication or vaccine including over -the-counter or 
prescription medicines, vitamins, and/or herbal supplements that the patient  is receiving at the 
time of enrolment or receives during the study must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
 
Anti -emetics/ Anti -diarrh eals 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 37 (94)  Should a patient develop nausea, vomiting and / or diarrhea , then these symptoms should be 
reported as AEs (see section 8.3) and appropriate treatment of the event given. 
Medications that may NOT be administered  
Table 4 Prohibited medicatio ns 
Prohibited medication/class of drug:   
Anticancer therapy:  
Chemotherapy  
Immunotherapy  
Hormonal therapy*  
Radiotherapy  (except palliative)  
Biological therapy  
Other novel agents  Not permitted while the patient is receiving study 
medication  
Live virus vaccines  
Live bacterial vaccines  Not permitted while the patient is receiving study 
medication  and during the 30 day follow up period.  
An increased risk of infection by the administration 
of live virus and bacterial vaccines has been observed 
with conventional chemotherapy drugs and the effects 
with olaparib are unknown.  
*Hormone Replacement Therapy (HRT) is acceptable  
 
 
Restricted concomitant medications  
 
Table 5  Restricted concomitant medications  
Medication/class of drug:  Usage (including limits  for duration permitted and 
special situations in which it’s allowed ):  
  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 38 (94)  Table 5  Restricted concomitant medications  
Medication/class of drug:  Usage (including limits  for duration permitted and 
special situations in which it’s allowed ):  
Strong CYP3A inhibitors:  
itraconazole, telithromycin, clarithromycin, 
boosted protease inhibitors, indinavir, saquinavir, nelfinavi r, boceprevir, 
telaprevir  
 
Moderate CYP3A inhibitors:  
ciprofloxacin, erythromycin, di ltiazem, 
fluconazole, verapamil   
 Strong or moderate CYP3A inhibitors should not 
be taken with olaparib .  If there is no suitable 
alternative concomitant medication then the dose 
of olaparib  should be reduced for the period of 
concomitant admini stration. The dose reduction 
of olaparib should be recorded in the CRF with the reason documented as concomitant CYP3A inhibitor use.  
• Strong CYP3A inhibitors – reduce the 
dose of olaparib to 100 mg daily for the 
duration of  concomitant therapy with the 
strong inhibitor and for 5 half lives afterwards.  
• Moderate CYP3A inhibitors – reduce the dose of olaparib to  100 mg twice daily for 
the duration of concomitant therapy with the moderate inhibitor and for 3 half lives afterward s. 
• After the washout of  the inhibitor is 
complete, the olaparib dose can be re-escalated.  
 
Strong inducers : 
phenobarbital, phenytoin, rifampicin, 
rifabutin, rifapentine, carbamazepine, nevirapine, enzalutamide and St John’s Wort  
 
Moderate CYP3A inducers : 
 bosentan, efavirenz and modafinil  Strong or moderate CYP3A inducers should not 
be taken with  olaparib.  
If the use of any strong or moderate CYP3A 
inducers are considered necessary for the 
patient’s safety and welfare this could diminish 
the clinical effi cacy of olaparib.  
If a patient requires use of a strong or moderate 
CYP3A inducer then they must be monitored 
carefully for any change in efficacy of  olaparib 
and TMZ.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 39 (94)  Table 5  Restricted concomitant medications  
Medication/class of drug:  Usage (including limits  for duration permitted and 
special situations in which it’s allowed ):  
• CYP3A4 substrates: hormonal 
contraceptive, simvastatin, cisapride, 
cyclosporine, ergot alkaloids, fentanyl, pimozide, sirolimus, tacrolimus and quetiapine  
• CYP2B6 substrates: bupropion, efavirenz  
• OATP1B1 substrates: bosentan, 
glibenclamide, repaglinide, statins and valsartan  
• OCT1, MATE1 and MATE2K substrates:  metformin  
• OCT2 substrates: serum creatinine  
• OAT3 substrates: furosemide, methotrexate  Effect of olaparib on other drugs  
Based on limited in vitro  data, olaparib may 
increase the exposure to substrates of CYP3A4, 
OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K.  
 Based on limited in vitro  data, olaparib  may 
reduce the exposure to substrates of 2B6.  
Caution should be observed if substrates of these isoenzymes or transporter proteins are co-administered.  
 
Anticoagulant therapy  Patients who are taking warfarin may participate 
in this trial; however, it is recommended that international normalised ratio (INR) be monitored carefully at least once per week for 
the first month, then monthly if the INR is stable. 
Subcutaneous heparin and low molecular weight heparin are permitted. 
Palliative radi otherapy  Palliative radiotherapy may be used for the 
treatment of pain at the site of bony metastases that were present at baseline, provided the investigator does not feel that these are indicative 
of clinical disease progression during the study 
period.  Study treatment should be discontinued for a minimum of 3 days before a patient 
undergoes therapeutic palliative radiation 
treatment.  Study treatment should be restarted within 4 weeks as long as any bone marrow toxicity has recovered.    
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 40 (94)  Table 5  Restricted concomitant medications  
Medication/class of drug:  Usage (including limits  for duration permitted and 
special situations in which it’s allowed ):  
Administration of other anti -cancer agents  
 Patients must not receive any other concurrent 
anti-cancer therapy, including investigational 
agents, while on study treatment. Patients may 
continue the use of bisphosphonates or 
denosumab for bone disease and corticosteroids 
for the symptomatic control of brain metastases provided the dose is stable before and during the 
study and they were started at least 4 weeks prior 
to beginning study treatment.  
  
 
6.5.1 Background medication 
6.5.2 Other concomitant treatment  
Other medication other than that described above, which is considered necessary for the patient ’s 
safety and wellbeing, may be given at the discretion of the Investigator and recorded in the 
appropriate se ctions of the Electronic Case Report Form.  
In addit ion, any unplanned diagnostic, therapeutic or surgical procedure performed during the 
study period must be recorded in the e CRF.  
 
6.6 Dose Modifications  
 
Dose Reductions  
In case a dose reduction is necessary, the Study treatments  will be administered as follows:  
Table 6  Dose reductions for olaparib  to manage adverse events  
Initial Dose  Following re -challenge post 
interruption: Dose reduction 1  Dose reduction 2  
150 mg twice daily  100 mg twice daily  100 mg once daily  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 41 (94)  Table 7  Dose reductions for TMZ  to manage adverse events  
Initial Dose  Following re -challenge post 
interruption: Dose reduction 1  Dose reduction 2  
75 mg / m2 (days 1 -7) 
*60 mg / m2 (days 1 -7) 
*50 mg / m2 (days 1 -7) 60 mg / m2 (days 1 -7) 
50 mg / m2 (days 1 -7) 
40 mg / m2 (days 1 -7) 50 mg / m2 (days 1 -7) 
40 mg / m2 (days 1 -7) 
30 mg / m2 (days 1 -7) 
* If the starting dose of TMZ  is lowered as described in section 4.2.  
Table 8  Dose reduction for  olaparib  and TMZ  if patient develops moderate 
renal impairment   
Initial Dose  Moderate renal impairment (calculated creatinine clearance by 
Cockcroft -Gault equation or based on a 24 hour urine test 
between 31 and 50 ml/min) : Dose reduction  
 
Olaparib: 150 mg twice daily  
TMZ: 75 mg / m2 (days 1 -7) 100 mg twice daily  
For TMZ no dose adjustments are required for moderate renal impairment.  
 
For TMZ no dose adjustments are required for renal impairment.  
Table 9  Dose reductions for olaparib  and TMZ if patient has to start taking a 
strong or moderate CYP3A inhibitor  
Initial Dose  Strong CYP3A inhibitor  Moderate CYP3A inhibitor 
Olaparib: 150 mg twice daily  
TMZ: 75 mg / m2 (days 1 -7) 100 mg daily  
For TMZ no dose adjustments 
are required for concomitant  
CYP3A4 inhibitors.  100 mg twice daily  
For TMZ no dose adjustments are required for concomitant 
CYP3A4 inhibitors.  
 
For TMZ no adjustments are require d for concomitant CYP3A inhibitors.  
For guidance on dose reductions for management of AEs (including renal impairment) refer to 
section 8.4.5. 
For guidance on dose reductions when concomitant strong or moderate CYP3A inhibitors cannot 
be avoided see section 6.5. 
When dose reduction for olaparib is necessary patient s will take  one 100 mg tablet twice (see 
Section 8.4.5 and Section 6.5) . 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 42 (94)  7. DISCONTINUATION OF T REATMENT AND PATIENT  
WITHDRAWAL  
7.1 Discontinuation of study treatment  
Patient s may be discontinued from investigational product (IP) in the following situations. Note 
that discontinuation from study treatment is NOT the same thing as a complete withdrawal from 
the study  
• Patient  decision. The patient  is at any time free to discontinue treatment, without 
prejudice to further treatment  
• Adverse Event  
• Severe non -compliance with the Clinical Study Protocol  
• Bone marr ow findings consistent with myelodysplastic syndrome (MDS)/acute 
myeloid leukaemia (AML)  
7.1.1 Procedures for discontinuation of s tudy treatment  
The investigator should instruct the patient  to contact the site before or at the time if Study 
treatment  is stopped. A patient  that decides to discontinue Study treatment  will always be asked 
about the reason(s) and the presence of any AEs .  The date of last intake of Study treatment  
should be documented in the CRF  (electronic or paper) .  All Study treatment should be returned 
by the patient  at their next on -site study visit or unscheduled visit .  Patient s permanently 
discontinuing Study treatment  should be given locally available  standard of care therapy, at the 
discretion of the Investigator. 
Any patient discontinuing investigational product should be seen post discontinuation for the 
evaluations and sample collections outlined in the study schedule .  
After discontinuation of the study medication at any point in the study, all ongoing AEs or SAEs must be fol lowed until resolution unless, in the Investigator’s opinion the condition is unlikely to 
resolve due to the patients underlying disease, or the patient is lost to follow up (see Section 7.2). All new AEs and SAE s occurring during the 30 calendar days after the last dose of study 
medication must be reported (if SAEs, they must be reported within 24 hours as described in 
Section 8.4.1) and followed to resolution as above. Pa tients should be seen at least 30 days after 
discontinuing study medication to collect and / or complete AE information. For guidance on 
reporting adverse events after the 30 day follow up period see Section 8.3.2.1. 
Discontinuation of Olaparib and TMZ , for any reason, does not impact on the patient ´s 
participation in the study .  The patient  should continue attending subsequent study visits and data 
collection should continue according to the study protocol .  If the patient  does not agree to 
continue in- person study visits, a modified follow -up must be arranged to ensure the collection 
of sur vival endpoints .  This could be a telephone contact with the patient  every 3 months  a 
contact with a relative or treating physician, or information from medical records .  The approach 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 43 (94)  taken should be recorded in the medical records .  A patient  that agrees to modified follow -up is 
not considered to have withdrawn consent or to have withdrawn from the study.  
7.2 Lost to follow -up 
Patients will be considered lost to follow -up only if no contact has been established after the site 
reaches out >3 times . Patients who refuse to continue participation in the study, including 
telephone contact, should be documented as “withdrawal of consent” rather than “lost to follow -
up.” Investigators should document attempts to re -establish contact with missing patients 
throughout the study period. If contact with a missing patient is re -established, the patient should 
not be considered lost to follow -up and evaluations should resume according to the protocol.  
In order to support key end point s of P FS and OS , the survival status of al l patients in the 
efficacy analysis set (ITT population)  and safety anal ysis set should be re -checked; this includes 
those patients who withdraw consent or are classified as “lost to follow -up.” 
• Lost to follow up – site personnel should check hospital records, the patient’s current 
physician, and a publicly available death registry (if available) to obtain a current survival status.  
• In the event that the patient has actively withdrawn consent to the processing of their personal data, the survival status of  the patient can be obtained by site personnel from 
publicly available death registries (if available) where it is possible to do so under applicable local laws to obtain a current survival status. 
7.3 Withdrawal from the s tudy  
Patients are free to withdraw from the study at any time, without prejudice for further treatment.  
A patient who withdraws consent will always be asked about the reason(s) and the presence of 
any AEs. The investigator will follow up AEs outside of the clinical study.  
If a patient with draws from participation in the study, then his/her enrolment code cannot be 
reused. Withdrawn patients will not be replaced.  
If a patient withdraws consent, they will be specifically asked if they are withdrawing consent to:  
• Further participation in the study including any further follow up (e.g. survival cals)  
• Withdrawal of consent to the use of their study generated data  
• Withdrawal of the use of any samples  
The status of ongoing, withdrawn (from the study) and “lost to follow -up” patients at the time of  
an OS analysis should be obtained by the site personnel  by checking patient notes, hospital 
records, contacting the patient’s general practitioner and checking publicly available death 
registries. In the event that the patient has actively withdrawn conse nt to the processing of their 
personal data, the vital status of the patient can be obtained by site personnel from publicly 
available resources where it is possible to do so under applicable local laws.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 44 (94)  7.4 Treatment Beyond Progression  
For patients that meet the criteria for progression of disease by RECIST (version 1.1) , but who 
are experiencing clinical benefit may be considered for treatment beyond progression (for 
example: patients with radiographically responding systemic disease, but progression of brai n 
metastases) . The treating investigator must receive approval from the overall principal 
investigator (Michael Cecchini) to continue study treatment beyond progression and the patient 
must meet all other eligibility  criteria . Patients being treated beyond progression should have 
imaging ( CT scan  or MRI)  4 weeks +/ - 7 days after the imaging  that revealed progression of 
disease by RECIST. If the subsequent imaging  shows stability or response , imaging  may return 
to the schedule outlined in the study calendar.  
8. STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarize d in the SoA. 
The investigator will ensure that the data are recorded on the e CRFs. The web based OnCore 
system will be used for data collection and handling.  
The investigator ensures the accuracy, completeness, legibility, and timeliness of the data recorded and of the provision of answers to data queries according to the Clinical Study 
Agreement. The investigator will sign the complete electronic CRFs. A copy of the completed 
electronic CRFs will be archived at the study site.  
Immediate safety concerns should be discuss ed with the overall principal investigator 
immediately upon occurrence or awareness to determine if the patient should continue or discontinue study treatment.  
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential patients 
meet all eligibility criteria. The investigator will maintain a screening log to record details of all patients screened and to conf irm eligibility or record reasons for screening failure, as applicable.  
Procedures conducted as part of the patient’s routine clinica l management (e.g. blood count) and 
obtained before signing of the ICF may be utilized for screening or baseline purposes provided 
the procedures met the protocol -specified criteria and were performed within the time frame 
defined in the SoA.  
8.1 Efficacy a ssessments  
This study will evaluate the primary endpoint of overall response rate by RECIST v1.1. The 
overall response rate will be calculated by the sponsor (Yale School of Medicine) as the 
proportion of patients that receive either a partial response or complete response by RECIST v1.1 ( Eur J Ca 45: 228- 247, 2009) .  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 45 (94)  Response Criteria:  
Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether 
target or non- target) must have reduction in short axis to <10 mm (<1 cm). 
Partial Response: A t least a 30% decrease in the sum of the diameters of target lesions, taking as 
reference the baseline sum diameters.  
Progressive Disease: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study  (this includes the baseline sum if that is the smallest on 
study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or more new lesions is also consider ed progression).  
Stable Disease:  Neither sufficient shrinkage to qualify as partial response nor sufficient increase 
to qualify for progressive disease, taking as reference the smallest sum diameters while on study.  
Progression- free survival, overall survi val and  safety are secondary endpoints  
8.1.2 Investigator RECIST 1.1 Imaging Review  
Radiological efficacy will be assessed by RECIST 1.1.  A baseline scan should be collected 
during screening (Day -28 to - 1) for disease staging and for use as a RECIST 1.1 baseline for the 
study. Computed tomography is  the preferred imaging modality; however other imaging 
modalities (eg, bone scan, MRI scan) may be required to define progression in equivocal cases. The imaging schedule is outline in the SoA, and if an unsche duled assessment is performed and 
the patient has not progressed, every attempt should be made to perform the subsequent assessments according to the original imaging schedule. For patients who discontinue treatment due to toxicity or other reasons in the absence of confirmed objective progression, tumor assessments should continue according to the schedule of assessments.  
8.1.3 Survival Assessments  
Overall survival is defined as the time from enro llment to the date of death from any cause. 
Progression free survival is defined as the time from enrol lment to the date of radiological 
confirmed progression or date of death from any cause.  
Assessments for survival must be made at months 3,6, and 9 (± 1 week); month 12 (± 2 weeks); 
and then every 6 months thereafter (±2 weeks) following treatment discontinuation as outlined in 
SoA.  Survival information may be obtained via telephone contact wi th the patient or when 
appropriate patient’s family, or by contact with the patient’s current physician. The details of first and  subsequent therapies for cancer  after discontinuation of treatment  will be collected.  
In addition, patients on treatment or i n survival follow -up will be contacted following the data 
cutoff for the primary analysis and all subsequent survival analyses to provide complete survival 
data. These contacts should generally occur within 7 days of the data cutoff. If patients are 
confir med to be alive or if the death date is after the data cutoff date, these patients will be 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 46 (94)  censored at the date of data cutoff. Death dates may be found by checking publicly available 
death registries, where allowed by local regulations. Safety  assessments  
Planned time points for all safety assessment s are provided in the SoA. 
8.2.1 Clinical s afety laboratory assessments  
Blood and urine samples for determination of clinical chemistry, hematology, and urinalysis will 
be taken at the times indicated in the assessment schedules and as clinically indicated (see the SoAs).  
Clinical laboratory safety tests, including serum pregnancy tests, will be performed in a licensed clinical laboratory according to local standard procedures. Sample tubes and sample sizes may 
vary depending on the laboratory method. Urine pregnancy will be performed using a licensed 
test (urine or serum pregnancy tests are acceptable). Abnormal clinically significant laboratory 
results should be repeated as soon as possible. 
Additional safety samples may be collected if clinically indicated at the discretion of the 
investigator. The date, time of collection, and results (values, units, and reference ranges) will be recorded in the appropriate eCRF.  
The laboratory variables to be measured are presented in Table 10  (clinical chemistry and 
hematology).  
Table 10 Laboratory safety variables  
Haematology/Haemostasis (whole blood)  Clinical Chemistry (serum or plasma)  
B-Haemoglobin (Hb)  S/P-Creatinine  
B-Leukocyte count  S/P-Bilirubin, total  
B-Absolute neutrophil count  S/P-Alkaline phosphatise (ALP)  
B-Absolute lymphocyte count  S/P-Aspartate transaminase (AST)  
B-Platelet count  S/P-Alanine transaminase (ALT)  
B-Mean cell volume (MCV)  S/P-Albumin   
S/P-Potassium   
S/P-Calcium, total  
 S/P-Sodium  
Urinalysis  (macroscopic w/reflex microscopic)  S/P-Urea or Blood Urea Nitrogen (BUN)  
U-Hb/Erythrocytes/Blood  S/P-Total Protein  
U-Protein/Albumin   
U-Glucose     
NB. In case a patient  shows an AST or  ALT ≥3xULN together  with total bilirubin ≥ 2xULN 
please refer to Appendix  A. Actions required in cases of increases in liver biochemistry and 
evaluation of Hy’s Law ’, for further instructions.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 47 (94)  
 Coagulation  
· Activated p artial th romboblastin time { APTT} will  be per formed at screenin g and if 
clinically indicated   
· International normalised ratio {INR} will be performed at screening and if clinically 
indicated. Patients taking warfarin may participate in this study; however, it is recommended that 
INR be monitored ca refully at least once per week for the first month, then monthly if the INR is 
stable.  
Each coagulation test result will be recorded in CRF.  
 Bone marrow or blood cytogenetic samples  
Bone marrow or blood cytogenetic samples may be collected for patients wit h prolonged 
haematological toxicities . 
Bone marrow analysis should include an aspirate for cellular morphology, cytogenetic analysis and flow cytometry, and a core biopsy for bone marrow cellularity. If it is not possible to 
conduct cytogenetic analysis or  flow cytometry on the bone marrow aspirate, then attempts 
should be made to carry out the tests on a blood sample. Full reports must be provided by the 
investigator for documentation on the Patient Safety database. These data are not required to be 
entered into CRF.  
 
8.2.2 Physical e xaminations  
Physical examinations will be performed accor ding to the assessment schedule (see the SoAs). 
Full physical examinations will include assessments of the head, eyes, ears, nose, and throat and 
the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermato;ogical, hematologic/lymphatic, and endocrine systems.   
8.2.3 Vital s igns 
Vital signs (blood pressure [BP], pulse, temperature, and respiratory rate) will be assessed according to the assessment schedule. Body weight is also recorded at each visit when vital signs are evaluated.  Height will be measured on day 1 only.  
BP and pulse measurements will be assessed with a completely automated device. Manual techniques will be used only if an automated device is not available.  
BP and pulse measurements should be preceded by at least 5 minutes of rest for the patient in a  
quiet setting without distractions (eg, television, cell phones).  
Vital signs will be measured in a semi- supine position after 5 minutes of rest and will include 
temperat ure, systolic and diastolic BP, pulse, and respiratory rate. Vital signs will be recorded in 
the eCRF.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 48 (94)  8.2.4 Electrocardiograms  
Resting 12- lead ECGs will be recorded at screening as clinically indicated th roughout the study 
(see the SoA ). ECGs should be obtained after the patient has been in a supine position for 5 
minutes and recorded while the  patient remains in that position.  
In case of clinically significant ECG abnormalities, including a QTcF value ≥ 470 ms, 2 
additional 12- lead ECGs should be obtained over  a brief period (eg, 30 minutes  to confirm the 
finding.  
Situations in which ECG result s should be reported as AEs are described in section 8.3.7. 
8.2.5 Other safety assessments  
If new or worsening pulmonary symptoms (eg, dyspnea) or radiological abnormality suggestive 
of pneumonitis/ILD is observed, toxicity management as described in detail in t he Dosing 
Modification and Toxicity Management Guidelines (see Section 8.4.5) will be applied.  The 
results of the full diagnostic workup (including high- resolution computed tomography [HRCT], 
blood and sputum culture, haematological parameters, etc) will be captured in the eCRF. It is strongly recommended to perform a full diagnostic workup, to exclude alternative causes such as 
lymphangitic carcinomatosis, infection, allergy, cardiogenic edema, or pulmonary haemorrhage. 
In the presence of a confirmatory HR CT scans where other causes of respiratory symptoms have 
been excluded, a diagnosis of pneumonitis (ILD) should be considered and the Dosing Modification and Toxicity Management Guidelines should be followed.  
Pneumonitis (ILD) investigation  
The following a ssessments, and additional assessments if required, will be performed to enhance 
the investigation and diagnosis of potential causes of pneumonitis. The results of the assessment will be collected.  
• Physical examination  
• Signs and symptoms (cough, shortness of breath, and pyrexia, ETC) including 
auscultation for lung field will be assessed.  
• Saturation of peripheral oxygen (SpO
2) 
• When pneumonitis (ILD) is suspected during study treatment, the following markers 
should be measured where possible:  
o ILD Markers (KL -6, SP -D) and β –D-GLUCAN  
o Tumor Markers: particular tumor markers that are related to disease progression 
o Additional chemist chemistry: CRP, LDH  
 Serum or urine pregnancy test  
Pregnancy tests on blood or urine samples will be performed for women of childbear ing potential 
within 28 days prior to the start of study treatment, on Day 1 of the study  prior to commencing 
treatment, on day 1 of every cycle, and at the 30 day follow up visit. Tests will be performed by the hospital’s local laboratory. If results are positive the patient is ineligible/must be discontinued 
from study treatment immediately.   Details of the pregnancy tests must be recorded in the 
patient’s medical records.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 49 (94)  8.3 Collection of adverse e vents  
The Principal Investigator is responsible for ensuring  that all staff involved in the study are 
familiar with the content of this section  
AE will be reported by the patient  (or, when appropriate, by a caregiver, surrogate, or the 
patient 's legally authorized representative).   
The investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE. For information on how to follow/up AEs see section 8.3.3.   
8.3.1 Method of d etecting AEs and SAEs  
Care will be taken n ot to introduce bias when detecting AEs and/or SAEs.  Open- ended and 
non-leading verbal questioning of the patient  is the preferred method to inquire about 
AE occurrences.   
8.3.2 Time period and frequency for collecting AE and SAE i nformation  
Adverse Events wi ll be collected from the time of signature of informed consent  throughout  the 
treatment  period and until  the 30-day follow -up period is completed. If an event that starts post 
the defined safety follow -up period noted above is considered to be due to a lat e onset toxicity to 
the study treatments then it should be reported as an AE or SAE as applicable. 
All SAEs will be recorded and reported to the s ponsor or designee within 24 hours, as indicated 
in Appendix  B.  The investigator will submit any updated SAE data to the sponsor within 24 
hours of it being available. 
Investigators are not obligated to actively seek AE or SAE in former study patient s. However, if 
the investigator  learns of any SAE, including a death, at any time after a patient ’s last visit and 
he/she considers the event to be reasonably related to the Study treatment  or study participation, 
the investigator may notify the sponsor.  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE re ports are provided in Appendix  B. 
 Adverse events after the 30 day follow up period  
For Pharmacovigilance purposes and characterisation, any SAE  of MDS/AML or new primary 
malignancy occurring after the 30 day follow up period should be reported to AstraZeneca 
Patient Safety regardless of investigator’s assessment of causality or knowledge of the treatment 
arm.  Investigators will be asked during t he regular follow up for overall survival if the patient 
has developed MDS/AML or a new primary malignancy and prompted to report any such cases.   
At any time after a patient has completed the study, if an Investigator learns of any SAE including sudden death of unknown cause, and he/she considers there is a reasonable possibility that the event is causally related to the investigational product, the investigator should notify AstraZeneca, Patient Safety . 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 50 (94)  If patients who are gaining clinical benefit are allowed t o continue study treatment post study 
completion then all SAEs must continue to be collected and reported to Patient Safety in the 
usual timeframe.  
Otherwise, after study treatment completion (i.e. after any scheduled post treatment follow -up 
period has ended) there is no obligation to actively report information on new AEs or SAEs 
occurring in former study patients. This includes new AEs/SAEs in patients still being followed up for survival but who have completed the post treatment follow up period (30 days).  
8.3.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each patient  at 
subsequent visits/contacts.  All  AEs/SAEs,  will be followed until resolution, stabilization, the 
event is otherwise explained, or the patient  is lost to follow -up  
Any AEs that are unresolved at the patient’s last visit in the study are followed up by t he 
investigator for as long as medically indicated  (this may be beyond the 30 days after the last dose 
of study treatmen t), but without further recording in the CRF.  AstraZeneca retains the right to 
request additional information for any patient  with ongoing AE(s)/SAE(s) at the end of the study, 
if judged necessary.  
Any SAE or non -serious adverse event that is ongoing at t he time of the 30 -day follow up, must 
be followed up to resolution unless the event is considered by the investigator to be unlikely to resolve, or the patient is lost to follow up. AstraZeneca retains the right to request additional information for any pa tient with ongoing AE(s)/SAE(s) at the end of the study, if judged 
necessary  
8.3.4 Adverse event data collection  
The following variables will be collect for each AE;  
• AE (verbatim)  
• The date when the AE started and stopped  
• CTCAE  v.5.0 grade and changes in CTCAE v.5.0 grade  
• Whether the AE is serious or not  
• Investigator causality rating against the Investigational Product (s) (yes or no) , 
comparator/combination drug (yes/no)  
• Action taken with regard to Investigational Product(s ) / comparator/combination drug 
• AE caused subject’s wit hdrawal from study (yes or no)  
• Outcome.  
In addition, the following variables will be collected for SAEs:  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 51 (94)  • Date AE met criteria for serious AE  
• Date Investigator became aware of serious AE  
• AE is serious due to  
• Date of hospitalisation  
• Date of di scharge  
• Probable cause of death  
• Date of death  
• Autopsy performed  
• Causality assessment in relation to Study procedure(s)  
• Causality assessment to other medication'  
• Description of AE  
The grading scales found in the revised NCI CTCAE version 5.0 will be utilized for all events 
with an assigned CTCAE grading. For those events without assigned CTCAE grades, the 
recommendation in the CTCAE criteria that converts mild, moderate, and severe events into CTCAE grades should be used. A copy of the CTCAE version 5.0 can be downloaded from the 
Cancer Therapy Evaluation Program website (http://ctep.cancer.gov).  
8.3.5 Causality collection  
The Investigator  will assess causal relationship between Investigational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do you consider that there is a 
reasonable possibility that the event may have been caused by the investigational product  or 
combination drug ?’ 
For SAEs,  causal relationship will also be assessed for other med ication and study procedures .  
Note t hat for SAEs that could be associated with any study procedure the causal relationship is 
implied as ‘yes’.  
A guide to the interpretation of the causality  question is found in Appendix B . 
8.3.6 Adverse events based on signs and symptoms  
All AEs spontaneously reported by the patien t or care provider,  reported in response to the open 
question from the study site staff: “ Have you  had any health problems since the previous 
visit/you were last asked? ,” or revealed by observation will be collected and recorded in the 
CRF.  When collecting AEs, the recording of diagnoses is preferred (when possible) to recording 
a list of signs and symptoms.  However, if a diagnosis is known and there are other signs or 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 52 (94)  symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom 
will be recorded separately.  
8.3.7 Adverse events based on examinations and tests  
The r esults from the  protocol mandated laboratory tests and vital signs will be summarised in the 
clinical study report (CSR) .  Deterioration as compared to baseline in protocol -mandated 
laboratory values and vital signs  should therefore only be reported as AEs if they fulfil  any of the 
SAE criteria or are the reason for discontinuation of treatment  with the investigational products . 
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE a nd the associated laboratory result/vital sign will 
be considered as additional information.  Wherever possible the reporting Investigator uses the 
clinical, rather than the laboratory term (e.g., anaemia versus low haemoglobin value).  In the 
absence of clinical signs or symptoms, clinically relevant deteriorations in non -mandated 
parameters should be reported as AE(s).  
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE. 
Any new or ag gravated clinically relevant abnormal medical finding at a physical examination as 
compared with the baseline assessment will be reported as an AE unless unequivocally related to 
the disease under study, see sections 8.3.9 and 8.310. 
8.3.8 Hy’s l aw 
Cases where a patient  shows elevations in liver biochemistry may require further evaluation and 
occurrences of AST or ALT ≥ 3xULN together with total bilirubin ≥ 2xULN may need to be 
reported as S AEs.  Please refer to Appendix A  for further instruction on cases of increases in 
liver biochemistry and evaluation of Hy’s Law  
8.3.9 Disease progression  
Disease progression can be considered as a worsening of a patient ’s condition attributable to the 
disease for which the investigational product is being studied.  It may be an increase in the 
severity of the disease under study and/or increases in the symptoms of the disease.  The development of new, or progression of existing metastasis to the primary cancer under study  
should be considered a s disease progression and not an AE.  Events, which are unequivocally 
due to disease progression, should not be reported as an AE during the study.  
8.3.10 New Cancers  
The development of a new primary cancer should be re porte d as an AE (see Section 8.3.13 
Olaparib  Adverse Events of Special Interest)  and would in most cases meet seriousness criteria 
(with the exception of some non- melanoma skin cancers). New primary malignancies are those 
that are not the primary reason for the administration of the study treatment and have developed 
after the inclusion of the patient into the study.  They do not include metastases of the original 
cancer.  Symptoms of metastasis or the metastasis itself should not be reported as an AE/SAE, as they are considered to be disease progres sion. 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 53 (94)  8.3.11 Lack of efficacy  
When there is deterioration in the cancer, for which the study treatment(s) is being used, may be 
uncertainty as to whether this is lack of efficacy or an AE.  In such cases, unless the the reporting 
physician  considers that the stud y treatment contributed to the deterioration of the condition, or 
local regulations state to the contrary, the deterioration should be considered to be a lack of 
efficacy and not an AE.  
8.3.12 Deaths  
All deaths that occur during the study, or within the protocol -defined 30- day post -study 
follow -up period after the administration of the last dose of study treatment, must be reported as 
follows:  
• Death clearly the result of disease progression should be reported to principal investigator and should be documented in the eCRF but should not be reported as an 
SAE.  
• Where death is not due (or not clearly due) to progression of the disease under study, the AE causing the death must be reported to the principal investigator and Astra 
Zeneca as a SAE  within 24 hours  (see Section 8.4.1 for further details).  The report 
should contain a comment regarding the co- involvement of progression of disease, if 
appropriate, and should assign main and contributory causes of death.  This 
information can be capture d in the  eCRF.  
Deaths with an unknown cause should always be reported as a SAE.  A post mortem maybe helpful in the assessment of the cause of death, and if performed a copy of the post -mortem 
results should be forwarded to AstraZeneca within the usual tim eframes.  
8.3.13 Olaparib adverse events of special interest  
Adverse events of special interest [AESI] are events of scientific and medical interest specific to the further understanding of olaparib’s safety profile and require close monitoring and rapid 
communica tion by the investigators to AstraZeneca. Adverse Events of Special Interest for 
olaparib are the Important Potential Risks of MDS/AML, new primary malignancy (other than 
MDS/AML) and pneumonitis.   
A questionnaire will be sent to the principal  investigato r if an AESI  is reported , as an aid to 
provide further detailed information on the event.  During the study there may be other events identified as AESIs that require the use of a questionnaire to help characterise the event and gain a better understanding  regarding the relationship between the event and study treatment.  
8.4 Safety reporting and medical m anagement  
8.4.1 Reporting of serious adverse events  
All SAEs have to be reported, whether or not considered causally related to the investigational product, or to the study procedure(s).  All SAEs will be recorded in the CRF.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 54 (94)  If any SAE occurs in  the course of the study, then i nvestigators or other site personnel inform the 
appropriate AstraZeneca representatives within one day i.e., immediately  but no later than 24 
hours of when he or she becomes aware of it . 
The designated AstraZeneca representative works with the i nvestigator to ensure that all the 
necessary information is provided to the AstraZeneca Patient Safety data entry site within 1  
calendar day  of initial receipt for fatal and life threatening events and within 5 calendar  days 
of initial receipt for all other SAEs.  
For fatal or life -threatening adverse events where important or relevant information is missing, 
active follow -up is undertaken imme diately.  Investigators or other site personnel inform 
AstraZeneca representatives of any follow -up information on a previously reported SAE within 
one calendar day i.e., immediately but  no later than 24 hours of when he or she becomes aware 
of it. 
For further guidance on the definition of a SAE, see Appendix  B. 
8.4.2 Pregnancy  
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca exce pt for:  
• If the pregnancy is discovered before the study patient has received any study drug  
Pregnancies in the partner of male patients (see Section 5.3 for lifestyle restrictions for male 
patients with a female partner of childbearing potential and Sectio n 8.4.2.2. for restrictions 
on male patients fathering a child)  
If a pregnancy is reported, the  investigator should inform Astra Zeneca within 24 hours of 
learning of the pregnancy.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, foetal  death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
 Maternal exposure  
If a patien t becomes pregnant during the course of the study , the investigational products should 
be discontinued immediately.  
Pregnancy itself is not regarded as an adverse event unless there is a suspicion that the 
investigational product under study may have interfered with the effectiveness of a contraceptive medication.  Congenital abnormalities/birth defects and spontaneous miscarriages should be 
reported and handled as SAEs.  Elective abortions without complications should not be handled 
as AEs.  The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth or congenital abnor mality) occurring from the date of the first dose of 
study medication until 6 months  after the last dose of study medication should be followed up 
and documented even if the patien t was discontinued from the study.  
If any pregnancy occurs in the course of the stu dy, then the Investigator or other site personnel 
informs overall principal investigator  who will discuss with the designated AstraZeneca 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 55 (94)  representative within 1  day i.e., immediately  but no later than 24 hours of when he or she 
becomes aware of it . 
The designated AstraZeneca representative works with the Investigator to ensure that all relevant 
information is provided to the AstraZeneca Patient Safety within 1 or 5 calendar days for SAEs (see Section 9.2.5) and within 30 days for all other pregnanci es. 
The same timelines apply when outcome information is available.  
 Paternal exposure  
Male patients should refrain from fathering a child or donating sperm during the study and for 3 months following the last dose  of the investigational products . 
Pregnancy of the patient’s partners is not considered to be an adverse event. However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, 
normal birth or congenital abnormality)  occurring from the date of the first dose until 3 months 
after the last dose should, if possible , be followed up and documented.  
8.4.3 Overdose  
There is currently no specific treatment in the event of overdose with olaparib or TMZ and 
possible symptoms of overdose are not established.  
Olaparib and TMZ  must only be used in accordance with the dosing recommendations in this 
protocol. Any dose or frequency of dosing that exceeds the dosing regimen specified in this 
protocol should be reported as an overdose. The Maximum Tolerated Dose is Olaparib 150 mg  
mg twice daily  (tablet)  (Days 1 -21) with TMZ 75 mg/m
2 (Days 1 -7). 
Adverse reactions associated with overdose should be treated symptomatically and should be managed appropriately.  
• An o verdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the CRF. 
If an overdose on an AstraZeneca study drug occurs in the course of the study, then the 
Investigator or other site personnel inform appropriate Astr aZeneca representatives immediately, 
or no later than 24 hours  of when he or she becomes aware of it.  
The designated AstraZeneca representative works with the Investigator to ensure that all relevant 
information is provided to AstraZeneca Patient Safety.  
For overdoses associated with a SAE, the standard reporting timelines apply, see Section 8.3.2.  
For other overdoses, reporting must occur within 30 days.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 56 (94)  8.4.4 Medication error  
If a medication erro r occurs  in the course of the study, then the Investigator or other site 
personnel informs the appropriate AstraZeneca representatives within 1 day i.e., immediat ely but 
no later than 24 hours of  when he or she becomes aware of it.  
The designated AstraZeneca representative works with the Investigator to ensure that all relevant 
information is completed within 1 (Initial Fatal/Life -Threatening or follow up Fatal/Life -
Threatening)  or 5 (other seriou s initial and follow up)  calendar days if there is an SAE associated 
with the medication error (see Section 8.3.2) and within 30 days for all other  medication errors.  
The definition of a Medication Error can be found in Appendix  B. 
8.4.5 Management of adverse events  related to Olaparib and TMZ  
Any t oxicity observed during the course of the study could be managed by interruption of the 
dose of  the attributed  study treatment or dose reductions. Repeat dose interruptions are allowed 
as required, for a maximum of 4 weeks on each occasion. If the interruption is any longer, the 
study team must be informed. Olaparib  treatment can be dose reduced to 100 mg twice daily. If 
the reduced dose of 100 mg twice daily is not tolerable, olaparib can be further dose reduced to 
100 mg daily, and if this is not tolerabl e no further dose reduction is allowed and study treatment 
should be discontinued. Temozolomide can be dose reduced to 60 mg/ m2 (Days 1 -7), and if this 
is not tolerable TMZ can be further dose reduced to 50 mg/ m2 (Days 1 -7). The following tables 
should be applied if an AE is deemed to be at least “possibly related” to olaparib, TMZ, or both. 
If an AE is only attributed to one of the agents the other agent may be continue at an unadjusted dose. 
Once dose is reduced, escalation is not permitted (except follow ing concomitant treatment with 
CYP3A4 inhibitors – see Section 6.5  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 57 (94)  
 Management of haematological toxicity 
Management of anaemia 
Table 11 Management of anaemia 
Haemoglobin  Action to be taken  
Hb < 10 but  ≥ 8 g/dl 
(CTCAE Grade 2) * First occurrence:  
Give appropriate supportive treatment and investigate causality.  
Investigator judgement to continue olaparib and TMZ  with supportive 
treatment (eg transfusion) or  interrupt dose for a maximum of 4 weeks. 
TMZ and olaparib  can be restarted if Hb has recover ed to > 9g/dl.  
Subsequent occurrences:  
If Hb < 10 but  ≥ 9 g/dl  investigator judgement to continue olaparib and 
TMZ with supportive treatment (eg transfusion) or  dose interrupt  (for max 
of 4 weeks) and upon recovery dose reduction may be considered for 
olaparib (to 100  mg twice daily as a first step and to 100 mg once  daily ) 
and for TMZ ( 60 mg/ m2 as a first step and to 50 mg/ m2 as a second step) . 
If Hb < 9 but  ≥ 8 g/dl , dose interrupt (for max of 4 weeks) until Hb ≥ 9 
g/dl and upon recovery dose reduction for olaparib may be considered ( to 
100 mg twice daily  as a first step and to 100 mg once  daily  as a second 
step). For TMZ a dose reduction may be considered (to TMZ 60 mg/  m2 
as a first step and to 50 mg/  m2 as a seco nd step).  
Hb < 8 g/dl  
(CTCAE Grade 3) * Give appropriate supportive treatment (e.g. transfusion) and investigate 
causality.  
Interrupt  olaparib and TMZ  for a maximum of 4 weeks  until improved to 
Hb ≥ 9 g/dl. 
Upon recovery , for olaparib dose reduce to 100 mg twice daily  as a first 
step and to 100 mg once  daily  as a second step in the case of repeat Hb 
decrease.  For TMZ dose reduce to TMZ 60 mg/ m2 as a first step and to 
50 mg/ m2 as a second step.  
 
* If the starting dose of TMZ  is lowered as described in section 4.2 the TMZ doses  should be 
adjusted per table 7 based on the starting dose.  
Common treatable causes of anaemia (e.g., iron, vitamin B12 or folate deficiencies and 
hypothyroidism) should be investigated and appropriately managed. In some cases manage ment 
of anaemia may require blood transfusions. For cases where patients develop prolonged haematological toxicity (≥2 week interruption/delay in study treatment due to CTC grade 3 or worse anaemia and/or development o f blood transfusion dependence) , refer  to guidance later in 
this section  for further management .  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 58 (94)  Management of neutropenia, leukopenia and thrombocytopenia  
Table 12 Management of neutropenia, leukopenia and thrombocytopenia  
Toxicity  Study treatment dose adjustment  
CTCAE Grade 1 -2 Investigator judgement to continue treatment or if dose interruption, this 
should be for a maximum of 4 weeks; appropriate supportive treatment 
and causality investigation  
CTCAE Grade 3 -4* Dose interruption until recovered to CTCAE gr 1 or better for a ma ximum 
of 4 weeks. If repeat CTCAE grade 3 -4 occurrence, dose reduce  olaparib 
to 100 mg twice daily as a first step and 100 mg once  daily as a second 
step and dose reduce TMZ to 60 mg/ m2 as a first step and 50 mg/ m2 as a 
second step.  
* If the starting dose of TMZ  is lowered as described in section 4.2 the TMZ dose  should be 
lowered  per table  7 based on the starting dose.  
Adverse event of neutropenia and leukopenia should be managed as deemed appropriate by the 
investigator with close f ollow up and interruption of study drug if CTC AE grade 3 or worse 
neutropenia occurs.  
Primary prophylaxis with Granulocyte colony -stimulating factor (G -CSF) is not recommended, 
however, if a patient develops febrile neutropenia, study treatment should be s topped and 
appropriate management including G -CSF should be given according to local hospital 
guidelines. Please note that G -CSF should not be used within at least 24 h (7 days for pegylated 
G-CSF) of the last dose of TMZ or olaparib  unless absolutely nece ssary.  
Platelet transfusions, if indicated, should be done according to local hospital guidelines.  
For cases where patients develop prolonged haematological toxicity (≥2 week interruption/delay 
in study treatment due to CTC AE grade 3 or worse), refer to guidance later in this section for the 
management of this.  
 
Management of prolonged haematological toxicities while on study treatment  
If a patient develops prolonged haematological toxicity such as:  
• ≥2 week interruption/delay in study treatment due to CTC AE grade 3 or worse 
anaemia and/or development of blood transfusion dependence  
• ≥2 week interruption/delay in study treatment due to CTC AE grade 3 or worse 
neutropenia (ANC < 1 x 109/L) 
• ≥2 week interruption/delay in study treatment due to CTC AE grade 3 or worse 
thrombocytopenia and/or development of platelet transfusion dependence (Platelets < 
50 x 109/L) 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 59 (94)  Check weekly differential blood counts including reticulocytes and peripheral blood smear. If 
any blood parameters remain clinically abnormal aft er 4 weeks of dose interruption, the patient 
should be referred to haematologist for further investigations. Bone marrow analysis and/or 
blood cytogenetic analysis should be considered at this stage according to standard 
haematological practice. Study treatment should be discontinued if blood counts do not recover 
to CTC AE gr 1 or better within 4 weeks of dose interruption. 
Development of a confirmed myelodysplastic syndrome or other clonal blood disorder should be 
reported as an SAE and full reports must be provided by the investigator to AstraZeneca Patient 
Safety. Study  treatment should be discontinued if patient’s diagnosis of MDS and/or AML is 
confirmed.  
 Management of non -haematological toxicity  
Repeat dose interruptions are allowed as required, for a m aximum of 4 weeks on each occasion. 
If the interruption is any longer than this the overall principal investigator  must be informed and 
confirm with the treating physician whether study treatments should continue .  Where toxicity 
reoccurs following re -challenge with study treatment, and where further dose interruptions are 
considered inadequate for management of toxicity, then the patient should be considered for dose reduction or must permanently discontinue study treatment.  
Olaparib can be dose reduced to  100 mg twice daily  as a first step and to 1 00 mg once  daily  as a 
second step , while TMZ can be dose reduced to 60 mg/m2 as a first step and 50 mg/m2 as a 
second step . Treatment must be interrupted if any NCI -CTCAE grade 3 or 4 adverse event 
occurs w hich the investigator considers to be related to administration of study treatment  and 
dose reductions considered or as outlined for specific adverse event management guidelines in section 8.4.5. If the investigator considers the adverse event to be related to only one of the study 
medications the other medication can continue uninterrupted after discussion with the overall principal investigator if felt to be safe in the opinion of the treating investigator.  
Management of new or worsening pulmonary symptom  
If new or worsening pulmonary symptoms (e.g., dyspnoea) or radiological abnormalities occur in 
the absence of a clear diagnosis, an interruption in study treatment dosing is recommended and 
further diagnostic workup (including a high resolution CT scan) s hould be performed to exclude 
pneumonitis.  
Following investigation, if no evidence of abnormality is observed on CT imaging and symptoms resolve, then study treatment can be restarted, if deemed appropriate by the investigator. If significant pulmonary abnormalities are identified, these need to be discussed with the principal 
investigator . 
Management of nausea and vomiting 
Events of nausea and vomiting are known to be associated with olaparib treatment. These events 
are generally mild to moderate (CTCAE gr ade 1 or 2) severity, intermittent and manageable on 
continued treatment. The first onset generally occurs in the first month of treatment for nausea 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 60 (94)  and within the first 6 months of treatment for vomiting. For nausea, the incidence generally 
plateaus at a round 9 months, and for vomiting at around 6 to 7 months. 
No routine prophylactic anti -emetic treatment is required at the start of study treatment, however, 
patients should receive appropriate anti -emetic treatment at the first onset of nausea or vomiting  
and as required thereafter, in accordance with local treatment practice guidelines.  Alternatively, olaparib and TMZ  tablets can be taken with a light meal/snack (ie 2 pieces of toast or a couple of 
biscuits).  
As per international guidance on anti -emetic use in cancer patients (ESMO, NCCN), generally a 
single agent antiemetic should be considered eg dopamine receptor antagonist, antihistamines or dexamethasone.  
Interruptions for intercurrent non -toxicity related events  
Study treatment dose interruption for  conditions other than toxicity resolution should be kept as 
short as possible. If a patient cannot restart study treatment within 4 weeks for resolution of intercurrent conditions not related to disease progression or toxicity, the case should be discusse d 
with overall principal investigator . 
All dose reductions and interruptions (including any missed doses), and the reasons for the reductions/interruptions are to be recorded in the eCRF.  
Study treatment should be stopped at least 3 days prior to planned surgery. After surgery study 
treatment can be restarted when the wound has healed. No stoppage of study treatment is required for any needle biopsy procedure.  
Study treatment should be discontinued for a minimum of 3 days before a patient undergoes radiati on treatment. Study treatment should be restarted within 4 weeks as long as any bone 
marrow toxicity has recovered.  
Because the AEs related to olaparib may include asthenia, fatigue and dizziness, patients should be advised to use caution while driving or using machinery if these symptoms occur.  
Table 13  Dose reductions for olaparib  
Initial Dose  Following re -challenge post 
interruption: Dose reduction 1  Dose reduction 2  
150 mg twice daily  100 mg twice daily  100 mg once  daily  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 61 (94)  Table 14  Dose reductions for TMZ  
Initial Dose  Following re -challenge post 
interruption: Dose reduction 1  Dose reduction 2  
75 mg /m2 (days 1 -7) 
*60 mg /m2 (days 1 -7) 
*50 mg /m2 (days 1 -7) 60 mg /m2 (days 1 -7) 
50 mg /m2 (days 1 -7) 
40 mg /m2 (days 1 -7) 50 mg /m2 (days 1 -7) 
40 mg /m2 (days 1 -7) 
30 mg /m2 (days 1 -7) 
* If the starting dose of TMZ  is lowered as described in section 4.2. 
 
 Renal impairment  
If subsequent to study entry and while still on study therapy, a patient’s estimated CrCl falls 
below the threshold for study inclusion (≥51 ml/min), retesting should be performed promptly.  
A dose reduction is recommended for patients who develop moderate  renal impairment 
(calculated creatinine clearance by Cockcroft -Gault equation or based on a 24 hour urine test of 
between 31 and 50 ml/min) for any reason during the course of the study: the dose of olaparib  
should be reduced to 100 mg twice daily.   
No dose reductions for TMZ are required for moderate to severe renal impairment, although 
caution is advised in cases of CrCl < 36 ml/min. Because the CrCl determination is only an 
estimate of renal function, in instances where the CrCl falls to between 31 and 50 mL/min, the 
investigator should use his or her discretion in determining whether a dose change or discontinuation of therapy is warranted.  
Olaparib has not been studied in patients with severe renal impairment (creatinine clearance  
≤ 30 ml/min) or end -stage renal disease; if patients develop severe impairment or end stage 
disease it is  recommended that study treatment be discontinued.  
8.5 Pharmacokinetics  
Pharmacokinetic parameters are not evaluated in this study.  
8.6 Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study.  
8.7 Genetics  
8.7.1 Collection of optional  genetic samples  
If the patient agrees to participate in the optional genetic research study, a blood sample will be collected. Participation is optional. Patients who do not wish to participate in the genetic research 
may still participate in the study. In the event of DNA extraction failure, a replacement genetic 
sample may be requested from the patient. Signed informed cons ent will be required to obtain a 
replacement sample unless it was included in the original consent.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 62 (94)  The blood and /or buccal swab  sample for genetic research will be obtained from the patient s at 
the screening visit .  Although DNA variants are stable parame ter, early sample collection is 
preferred to avoid introducing bias through excluding patient s who may withdraw due to an 
adverse event (AE), such patient s would be important to include in any genetic analysis.  If for 
any reason the sample is not drawn at  the screening visit, it may be taken at any visit until the 
last study visit.  
Samples will be collected, labelled, stored and shipped as deta iled in the Laboratory Manual.  
8.7.2 Storage and destruction of genetic samples  
The processes adopted for the coding and storage of samples for genetic analysis are important to 
maintain patient confidentiality. Samples may be stored for a maximum of 15 years or as per local regulations from the date of the patient’s last visit, after which they will be destroyed. DNA 
is a finite resource that may be used up during analyses. The results of any further analyses will 
be reported either in the CSR itself or as an addendum or separately in a scientific report or 
publication. 
No personal details identifying individual will be available to AstraZeneca or designated 
organizations working with the DNA.  
8.8 Biomarkers  
MGMT Promoter Hypermethylation Testing (integral biomarker):  
Existing archival tumor  biopsy  samples will be used for pre -screening , and when slides are 
provided at least 10 unstained slides must be submitted. Methylation status of the human MGMT promoter on chromostome 10 will be performed in formal fixed paraffin embedded tissue, by 
sodium bisulfite conversion followed by multiplex PCR. The analysis will be performed in t he 
CLIA certified pathology laboratory of Dr. Pei Hui  at Yale University School of Medicine in 
collaboration with Dr. Sklar in the Yale Clinical Molecular Pathology Laboratory . Please refer to 
the Laboratory Services Manual for additional details regardin g testing for MGMT Promoter 
Hypermethylation.  
Exploratory biomarkers:  
By participating in this study, the patient consents to the mandatory collection of tumor tissue 
(pre-treatment biopsy) and use of donated biological samples as described here. Tissue samples 
will be obtained from all screened patients.  
Mandatory tumor and blood biomarkers to be evaluated to support the exploratory objectives of the study are described below. Alternative biomarkers may be evaluated as determined by additional data assoc iated with disease progression/recurrence or response to the investigational 
treatment.  
Biomarker assessments that may have the potential to identify patients likely to respond to treatment with olaparib and TMZ (determined from other studies with olaparib  +/- TMZ) will be 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 63 (94)  investigated to determine a patient’s biomarker status and for possible correlation with efficacy 
endpoints. 
• Tumour biopsies will be taken at baseline and  at progression for investigation of next 
generation sequencing profiling, patterns of DNA methylation and gene expression, 
γH2AX, changes in the immune composition of the tumor microenvironment, 
resistance mechanisms, and other exploratory endpoints  to evaluate their association 
with the observed clinical responses to olaparib and TMZ.  
• Please refer to the Central Laboratory Services Manual for further details regarding 
sample collection, shipping and storage . 
Biomarkers will be tested in blood to evaluate their association with the observed clinical responses to olaparib and TMZ.  
In addition, blood will be collected  and an analysis may be performed on biomarker variants 
thought to play a role in DNA repair  including, but not limited to, candidate genes/genome -wide 
analysis for RNA, serum analytes, or tissue biomarkers  to evaluate their association with  
observed clinical responses to olaparib and TMZ . 
Other samples may be used for research to develop methods, assays, prognostic s and/or 
companion diagnost ics related to  MGMT promoter hypermethylation / silencing and DNA 
repair.   
Any sample material remaining after completion of analyses to fulfil the study objectives may be used for opt ional exploratory research to develop methods, assays, prognostics , and/or 
companion diagnostics  related to colorectal cancer, MGMT promoter hypermethylation / 
silencing, PARP, and DNA repair.  
The biomarker data will have unknown clinical significance and the results will not be provided to patients, their family members,  any insurance company or employer.  
The exploratory biomarker plan is described by sample type below.  
Fresh Tumor Tissue  
A sample of fresh tumor tissue will be used to create colorectal carcinoma organoids  and/or 
patient derived xenograft . 
Whole blood gen e expression  
Whole blood samples will be obtained from all patients at the time  points described in the SoA. 
The focus is likely to be given to the expression of DNA repair genes including but not limited to MGMT and immunomodulatory markers. Correlation w ith outcome data will be completed on 
select candidates, and predictive markers, with the aim of identifying useful expression thresholds for identifying patients likely to receive benefit.  
Serum -based markers  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 64 (94)  Serum will be obtained to explore the expressi on of cytokines and chemokine. 
Plasma -based markers (ctDNA, circulating soluble factors)  
Plasma will be obtained from all patients as described in the SoAs. The concentration of a panel 
of relevant cytokines, chemokines, and other DNA damage and immune -related markers may be 
assessed. Plasma may also be used to evaluate mutant circulating tumor DNA. Overall mutational burden and/or somatic mutations/genomic alterations in plasma may be assessed using state -of-the-art methodologies. Such measurements may be correlated with response.  
8.8.1 Storage, re -use and destruction of biomarker samples  
Samples will be stored for a maximum of 15 years from the date of the last p atient ’s last v isit, 
after which they will be destroyed.  The results of this biomarker research wil l be reported either 
in the CSR itself or as an addendum, or separately in a scientific report or publication . The 
results of this biomarker research may be pooled with biomarker data from other studies with the study drug to generate hypotheses t o be tested in future research.  
9. STATISTICAL CONSIDERATIONS  
9.1 Statistical hypotheses  
The primary objective of this study is to assess the efficacy of temozolomide in combination with olaparib in subjects with MGMT promoter hypermethylated advanced colorectal canc er 
who have progressed on at least one line of systemic chemotherapy by overall response rate as assessed per RECIST v.1.1. We hypothesize that the underlying response rate to the combination therapy is 25% or greater (H
1) compared to a null hypothesis of 5% (H 0) based on historical 
controls. 
9.2 Sampl e size determination  
The sample size estimation for the single -arm of this phase II study is based on the primary 
endpoint of objective response rate (ORR). The protocol plans to enroll a total of 30 evaluable 
patients  at the recommended dose level  in a single -arm open label phase 2 study Simon’s Two-
Stage optimal design.  There will be screening for eligibility and we will examine several 
secondary endpoints. Patients will be considered evaluable for the primar y endpoint if they 
complete at least 1 cycle of study treatment followed by  response assessment imaging. Patients 
that are not evaluable may  be replaced to ensure the appropriate number of evaluable patients is  
enrolled as outlined in the sample size deter mination for the primary endpoint in  the Simon’s 
two-stage optimal design described below .  
Screen:  To be eligible for this trial, patients will first need to be screened for the MGMT 
promoter hypermethylation and/or MGMT lack of expression. We anticipate at least 20% of 
those screened will exhibit an appropriate biomarker as well as meet eligibility cr iteria. To obtain 
30 eligible patients, the mean number of patients to be screened is 150.  Using the negative 
binomial distribution as reference, there is a 6% probability more than 190 subjects will need to be screened to attain the 30 eligible patients.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 65 (94)  The primary endpoint  is the objective response rate to the combined therapy and will be 
assessed in a Simon’s two -stage optimal design.  Published, historical records anticipate a 
response rate of 5% or lower and we will assume a null hypothesis of 5%. We  will reject this null 
hypothesis in favor of a higher rate if we observe 4 or more responses in the evaluable patient 
sample of 30. Patients will be considered evaluable for the primary endpoint if they complete at 
least 1 cycle of study treatment with  response assessment imaging. The trial will terminate early 
if we do not observe 1 or more responses in the first 9 evaluable patients. The probability of 4 or 
more responses in a sample of 30 has probability .049, which is the significance level.  If the 
true, underlying response rate is 25% or greater, then this trial has power 90%. The expected 
sample size is 17 under the null hypothesis.  There is a 63% chance of stopping early under the null hypothesis.  
9.3 Populations for a nalyses 
Table 15. 
Outcome variabl e Populations  
Efficacy Data   
     ORR  Efficacy analysis set (ITT population)  
     PFS Efficacy analysis set (ITT population)  
     OS Efficacy analysis set (ITT population)  
Safety Data   
     AEs Safety analysis set  
     ECOG performance status  Safety analysis set  
AE Adverse events; ORR Overall response rate; PFS Progression free survival; OS Overall survival; ECOG Eastern Cooperative Oncology Group; ITT Intention to treat  
All Subject Analysis Set  
The All Subject Analysis Set will include infor mation from all screened subjects, including those 
who did not meet the study entry criteria or did not receive a study treatment. This data set will 
only be used for disposition in which all screened subjects are accounted for. 
Efficacy  Analysis Set (ITT population)  
The Efficacy Analysis Set will include all subjects who receive any amount of study treatment 
for efficacy analyses. Efficacy analyses will be based on the actual treatment received. The ORR 
analysis will be based on subjects who are in the Eff icacy Analysis Set and who had disease 
assessment at baseline and at least 1 follow up disease assessment or subjects who died or 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 66 (94)  stopped treatment before the first scheduled disease assessment due to clinical progression or 
toxicity.  
Safety Analysis Set  
The Safety Analysis Set will include data from all subjects who receive any amount of study 
drug. Safety analysis will be based on the actual treatment received. All data will be included, and no subjects excluded because of protocol violations. 
Schedule of  Analysis  
This is an open- label study. Ongoing analyses to help manage the study and support the DS MC 
reviews for safety and antitumor activity will be undertaken. A final analysis will be conducted 
after all subjects have completed the study.  
Disposition   
The number and percentage (n, %) of subjects enrolled, treated, lost to follow -up, and withdrawn 
from treatment or discontinued from the study (with reason) will be summarized. The sample 
sizes for the Efficacy Analysis Set, Safety Analysis Set will be clearly identified. All subjects in 
the All Subject Analysis Set will be included in the disposition analysis.  
9.4 Statistical analyses 
We will use intention to treat (ITT) analysis for the primary and secondary endpoints.  
9.4.1 Efficacy a nalyses  
Primary Endpoint: Overall response rate (ORR) by RECIST v1.1 criteria for combined therapy 
of olaparib and temozolomide.  
Analytic Plan for Primary Endpoint:  
The objective response is defined as a complete or partial response, as determined by 
investigator assessment using  RECIST v 1.1 and confirmed by repeated assessment > 4 weeks 
after initial documentation. Patients with missing or no response assessments are classified as 
non-responders. The trial will terminate early if we do not observe 1 or more responses in the 
first 9 evaluable patients. The ORR will be estimated using the 95% confidence interval (CI) 
based on Wilson’s method. A 5% 2- sided alpha will be used. 
Secondary Endpoints: PFS, OS, Safety  
Analysis Plans for Secondary Endpoints:  
Secondary endpoints include overall survival, progression- free survival, and toxicity. Survival 
endpoints will be plotted using the Kaplan- Meier, product -limit method and compared across 
clinical measurements using Cox proportional hazards regression.  Time to progression begins at 
the time of initial treatment and ends at the earliest of withdrawal, diagnosed progression, or 
death. For PFS subjects who are alive and have not progressed will be censored at the date of 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 67 (94)  their last RECIST tumor assessment. For OS subjects who are alive will be censored at the date 
of their last survival assessment. Toxicity rates will be compared to established rates for these 
treatments and summarized using means and 95% confidence intervals.   
9.4.2 Safety analyses  
Adverse events (AEs) will be listed and tabul ated for patients on treatment. AEs will be 
classified  based on the likelihood that they are treatment -related. NCI toxicity Grade 3 and Grade 
4 laboratory abnormalities will also be listed.  
9.4.3 Other a nalyses  
Exploratory endpoints:  
Genetic markers will be p lotted using heat -maps and statistically compared across responders 
and non- responders using the Benjamini -Hochberg correction for multiplicity of p -values.  
9.4.4 Methods for multiplicity control  
This is a single arm study with an integral biomarker therefore no  adjustments for multiplicity 
are planned  other than that mentioned in section 9.4.3 for the exploratory endpoints. 
9.5 Interim analyses   
An interim efficacy analysis will be performed after the first 9 patients are evaluated to 
determine whether or not to terminate the trial for futility, as noted in section 9.4.  
9.5.1 Data  monitoring committee  (DMC)  
The study principal investigator and YCCI are responsible for monitoring the performance of all of the participating investigators. This will be performed by conduct ing a study site initiation 
visit as well as regularly scheduled monitoring visits and/or remote monitoring throughout the 
life of the protocol. At the end of the trial, the monitor will then perform a study site close -out 
visit.  
YCCI will utilize their in stitution’s initiation, monitoring and close -out visit reports. Following 
each site visit, a visit report will be generated containing information on site activities, and a 
summary of pertinent points and action items together with a copy of the follow -up letter will be 
sent to each investigative site.  
During these monitoring visits, some of the items that will be reviewed are the following:  
• Training of the sites  
• Site personnel qualifications to participate in the trial 
• That study related documents are current  
• That regulatory compliance is accomplished  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 68 (94)  • That each subject has signed the informed consent  
• That the current and approved protocol is complied with (including reporting and  
logging of all protocol deviations)  
• That all SAEs and AEs have  been reported to the local regulatory and Ethics/IRB  
Committees, YCCI and Astra Zeneca, as appropriate 
• That source documentation matches CRFs  
• That required procedures for study drug accountability, distribution, and storage are  
followed. 
YCCI will doc ument the required study monitoring activities in a Study Monitoring Plan.  
9.5.2 Safety Monitoring 
The Yale Cancer Center Data and Safety Monitoring Committee (DSMC) will provide the 
primary oversight of data and safety monitoring. The Yale DSMC will review and monitor 
compliance, toxicity and deviations from this study. The committee is composed of clinical specialists with experience in oncology and who have no direct relationship with the study. 
Information that raises any questions about participant safety wi ll be addressed with the Principal 
Investigator.  
The DSMC will review this protocol at a minimum of once every six months. Information to be provided to the committee includes: a study narrative by the PI, a summary DSMC report 
produced by OnCore (which i ncludes participant accrual, response, trial status history, SAEs, 
Adverse Events, Deviations and survival); audit results, and monitoring reports as applicable. Other information (e.g. scans, laboratory values) will be provided upon request. 
The Yale DSMC  will perform an interim safety analysis after 15 patients have received at least 1 
cycle (28 days) of treatment to determine whether there are any safety issues and to assess 
whether it is safe to continue enrollment. Enrollment will be suspended until approval is granted 
from the DSMC to proceed completion of enrollment.  
If a new unexpected toxicity is identified from the above safety review, or if the periodic review 
of all the adverse events and laboratory data raises safety concerns, it may result in revision of 
the consent form, amendment of the protocol and/or suspension of the protocol. 
  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 69 (94)  10. REFERENCES  
FDA Guidance for Industry (issued July 2009) ‘Drug- induced liver injury: Premarketing clinical 
evaluation’  
Chan et al 2002  
Chan KYK, Ozcelik H, Cheung ANY, Ngan HYS, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002:62:4151- 4156. 
 
Cronin et al 2018 
Cronin, K. A., A. J. Lake, S. Scott, R. L. Sherman, A. M. Noone, N. Howlader, S. J. Henley, R. 
N. Anderson, A. U. Firth, J. Ma, B. A. Kohler and A. Jemal (2018). "Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics." Can cer 124(13): 2785- 2800.  
 Fong et al 2009  
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui -Roelvink M, et al. Inhibition of poly(ADP -
ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123- 34. 
Fulton et al 2017  
Fulton, B., S. C. Short, A. James, S. Nowicki, C. McBain, S. Jefferies, C. Kelly, J. Stobo, A. Morris, 
A. Williamson and A. J. Chalmers (2017). "PARADIGM -2: Two parallel phase I studies of 
olaparib and radiotherapy or olaparib and radiotherapy plus temozol omide in patients 
with newly diagnosed glioblastoma, with treatment stratified by MGMT status." Clinical and 
translational radiation oncology  8: 12- 16. 
 
Halford et al 2017  
Halford, S. E. R., G. Cruickshank, L. Dunn, S. Erridge, L. Godfrey, C. Herbert, S. J efferies, J. S. 
Lopez, C. McBain, M. Pittman, R. Sleigh, C. Watts, M. F. Webster -Smith and A. J. Chalmers 
(2017). "Results of the OPARATIC trial: A phase I dose escalation study of olaparib in 
combination with temozolomide (TMZ) in patients with relapsed g lioblastoma (GBM)." 
Journal of Clinical Oncology  35(15_suppl): 2022- 2022.  
 
Hay et al 2009 
Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP -ribose) 
polymerase- 1 inhibitor treatment regresses autochthonous Brca2/p53- mutant mammary  tumors 
in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 2009;69(9):3850-
5.  
Helleday 2011 
Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Molecular Oncology 2011; 5: 387- 393. 
Murai et al 2012  
Murai J, Huang SN, Das BB, Renaud A, Zhnag, Y, Doroshow, JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. AACR; 72(21); 5588–99. 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 70 (94)  Muratore et al 2007  
Muratore, A., D. Zorzi, H. Bouzari, M. Amisano, P. Massucco, E. Sperti and L. Capussotti 
(2007). "Asymptomatic Colorectal Cancer with Un- Resectable Liver Metastases: Immediate 
Colorectal Resection or Up -Front Systemic Chemotherapy?" Annals of Surgical Oncology  14(2): 
766-770. 
 
Narod and Foulkes 2004  
Narod SA and Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 
2004;4(9):665- 76. 
Nguewa et al 2005  
Nguewa PA, Fuertes MA, Valladares B, Alonso C, Perez JM. Poly(ADP -ribose) polymerases: 
homology, structural domains and functions. Novel therapeutic applications. Progr Biophys Mol 
Biol 2005;88:143- 172. 
Rottenberg et al 2008  
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High 
sensitivity of BRCA1- deficient mammary  tumors to the PARP inhibitor AZD2281 alone and in 
combination with platinum drugs. Proc Natl Acad Sci. 2008;105(44):17079- 84. 
Virag and Szabo 2002  
Virag L and Szabo C. The therapeutic potential of poly(ADP -Ribose) polymerase inhibitors. 
Pharmacol Rev 2002;54(3):375- 429. 
 
Bae, S. I. (2002). "Inactivation of O6 -methylguanine- DNA methyltransferase by promoter 
CpG island hypermethylation in gastric cancers." British journal of cancer  86(12): 1888-
1892.  
 
Brandes, A. A. (2006). "Correlations B etween O6 -Methylguanine DNA Methyltransferase 
Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study." Journal of 
clinical oncology  24(29): 4746- 4753.  
 
Chinot, O. L. (2007). "Correlation Between O - Methylguanine- DNA Methyltransferase and 
Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide." Journal of clinical oncology  25(12): 1470- 1475.  
 
Clark, O. (2016). "M olecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer." 
Clinical cancer research  22(8): 1837- 1842.  
 
Esteller, M. (1999). "Inactivation of the DNA repair gene O6 -methylguanine- DNA 
methyltransferase by promoter hypermethylation is a common event in primary human 
neoplasia." Cancer research (Chicago, Ill.)  59(4): 793.  
 
Hegi, M. E. (2005). "Gene Silencing and Benefit from Temozolomide in Glioblastoma." The 
New England journal of medicine 352(10): 997 -1003.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 71 (94)   
Konduri, S. D. (2009). "Blockade of MGMT exp ression by O6 benzyl guanine leads to 
inhibition of pancreatic cancer growth and induction of apoptosis." Clinical cancer research  
15(19): 6087 -6095.  
 
Kulke, M. H. (2009). "O6- methylguanine DNA methyltransferase deficiency and response to 
temozolomide -based therapy in patients with neuroendocrine tumors." Clinical cancer 
research  15(1): 338- 345.  
 
Noushmehr, H. (2010). "Identification of a CpG island meth ylator phenotype that defines a 
distinct subgroup of glioma." Cancer cell  17(5): 510- 522.  
 
Thomas, A. (2017). "Temozolomide in the Era of Precision Medicine." Cancer research 
(Chicago, Ill.)  77(4): 823- 826.  
 
Turcan, S. (2012). "IDH1 mutation is sufficient to establish the glioma hypermethylator 
phenotype." Nature (London)  483(7390): 479 -483.  
 
van den Bent, M. J. (2013). "MGMT -STP27 methylation status as predictive marker for 
response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report fr om 
EORTC study 26951." Clinical cancer research  19(19): 5513 -5522.  
 
Walter, T. (2015). "O6- Methylguanine- DNA methyltransferase status in neuroendocrine 
tumours: prognostic relevance and association with response to alkylating agents." British 
journal of ca ncer  112(3): 523- 531.  
 
Amatu, A., L. Barault, C. Moutinho, A. Cassingena, K. Bencardino, S. Ghezzi, L. Palmeri, E. Bonazzina, F. Tosi, R. Ricotta, T. Cipani, P. Crivori, R. Gatto, G. Chirico, G. Marrapese, M. Truini, A. Bardelli, M. Esteller, F. Di Nicolantonio, A. Sartore -Bianc hi and S. Siena (2016). 
"Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer." Ann Oncol  27(6): 1062- 1067. 
 
Amatu, A., A. Sartore- Bianchi, C. Moutinho, A. Belotti, K. Bencardino, G. Chirico, A. 
Cassingena, F. Rusconi, A. Esposito, M. Nichelatti, M. Esteller and S. Siena (2013). "Promoter 
CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to 
dacarbazine in a phase II study for metastatic colo rectal cancer." Clin Cancer Res  19(8): 
2265- 2272.  
 
Bae, S. I. (2002). "Inactivation of O6 -methylguanine- DNA methyltransferase by promoter 
CpG island hypermethylation in gastric cancers." British journal of cancer  86(12): 1888-
1892.  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 72 (94)  Barault, L. (2015). "Di gital PCR quantification of methylation refines prediction of clinical 
benefit from alkylating agents in glioblastoma and metastatic colorectal cancer." Annals of 
oncology  26(9): 1994- 1999.  
 
Barvaux, V. A. (2004). "Sensitization of a human ovarian cancer c ell line to temozolomide 
by simultaneous attenuation of the Bcl -2 antiapoptotic protein and DNA repair by O6 -
alkylguanine- DNA alkyltransferase." Molecular cancer therapeutics  3(10): 1215.  
 
Borger, D. R., K. K. Tanabe, K. C. Fan, H. U. Lopez, V. R. Fantin, K. S. Straley, D. P. Schenkein, 
A. F. Hezel, M. Ancukiewicz, H. M. Liebman, E. L. Kwak, J. W. Clark, D. P. Ryan, V. Deshpande, D. Dias -Santagata, L. W. Ellisen, A. X. Zhu and A. J. Iafrate (2012). "Frequent Mutation of 
Isocitrate Dehydrogenase (IDH)1 and I DH2 in Cholangiocarcinoma Identified Through 
Broad -Based Tumor Genotyping." The Oncologist  17(1): 72- 79. 
 
Boulton, S., L. C. Pemberton, J. K. Porteous, N. J. Curtin, R. J. Griffin, B. T. Golding and B. W. 
Durkacz (1995). "Potentiation of temozolomide- induc ed cytotoxicity: a comparative study 
of the biological effects of poly(ADP -ribose) polymerase inhibitors." British Journal Of 
Cancer  72: 849.  
 
Brandes, A. A. (2006). "Correlations Between O6 -Methylguanine DNA Methyltransferase 
Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in 
Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study." Journal of 
clinical oncology  24(29): 4746- 4753.  
 
Calabrese, C. R., R. Almassy, S. Barton, M. A. Batey, A. H. Calvert, S. Canan -Koch, B. W. 
Durkacz, Z. Hostomsky, R. A. Kumpf, S. Kyle, J. Li, K. Maegley, D. R. Newell, E. Notarianni, I. J. Stratford, D. Skalitzky, H. D. Thomas, L. -Z. Wang, S. E. Webber, K. J. Williams and N. J. Curtin 
(2004). "Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-
ribose) Polymerase- 1 Inhibitor AG14361." JNCI: Journal of the National Cancer Institute 
96(1): 56 -67. 
 
Calegari, M. A., A. Inno, S. Monterisi, A. Orlandi, D. Santini, M. Basso, A. Cassano, M. Martini, T. Cenci, I. de Pascalis, F. Camarda, B. Barbaro, L. M. Larocca, S. Gori, G. Tonini and C. Barone 
(2017). "A phase 2 study of temozolomide in pretreated metas tatic colorectal cancer with 
MGMT promoter methylation." Br J Cancer  116(10): 1279- 1286.  
 
Ceccarelli, M., F. P. Barthel, T. M. Malta, T. S. Sabedot, S. R. Salama, B. A. Murray, O. Morozova, Y. Newton, A. Radenbaugh, S. M. Pagnotta, S. Anjum, J. Wang, G. Ma nyam, P. 
Zoppoli, S. Ling, A. A. Rao, M. Grifford, A. D. Cherniack, H. Zhang, L. Poisson, C. G. Carlotti, Jr., D. P. Tirapelli, A. Rao, T. Mikkelsen, C. C. Lau, W. K. Yung, R. Rabadan, J. Huse, D. J. Brat, N. L. Lehman, J. S. Barnholtz -Sloan, S. Zheng, K. Hess, G. Rao, M. Meyerson, R. Beroukhim, L. 
Cooper, R. Akbani, M. Wrensch, D. Haussler, K. D. Aldape, P. W. Laird, D. H. Gutmann, T. R. Network, H. Noushmehr, A. Iavarone and R. G. Verhaak (2016). "Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma." Cell  164(3): 
550- 563.  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 73 (94)  Chen, F., K. Bian, Q. Tang, B. I. Fedeles, V. Singh, Z. T. Humulock, J. M. Essigmann and D. Li 
(2017). "Oncometabolites d - and l -2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair 
Enzymes under Physiological Conditions." Chem Res Toxicol 30 (4): 1102- 1110.  
 
Chinot, O. L. (2007). "Correlation Between O - Methylguanine- DNA Methyltransferase and 
Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolom ide." Journal of clinical oncology  25(12): 1470- 1475.  
 
Cimprich, K. A. and D. Cortez (2008). "ATR: an essential regulator of genome integrity." Nature Reviews Molecular Cell Biology  9: 616.  
 
Clark, O. (2016). "Molecular Pathways: Isocitrate Dehydrogenase M utations in Cancer." 
Clinical cancer research  22(8): 1837- 1842.  
 
Curtin, K., M. L. Slattery and W. S. Samowitz (2011). "CpG island methylation in colorectal 
cancer: past, present and future." Pathology research international  2011: 902674- 902674.  
 
Curtin, N . J., L.- Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan- Koch, S. E. Webber, B. W. 
Durkacz, H. A. Calvert, Z. Hostomsky and D. R. Newell (2004). "Novel Poly(ADP -ribose) 
Polymerase- 1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatc h 
Repair -Deficient Cells." Clinical Cancer Research  10(3): 881- 889.  
 
Delaney, C. A. (2000). "Potentiation of temozolomide and topotecan growth inhibition and 
cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of 
human tumor cell lines." Clinical cancer research  6(7): 2860.  
 
Esteller, M. (1999). "Inactivation of the DNA repair gene O6 -methylguanine- DNA 
methyltransferase by promoter hypermethylation is a common event in primary human neoplasia." Cancer research (Chicago, Il l.) 59(4): 793.  
 
Esteller, M. and J. G. Herman (2004). "Generating mutations but providing 
chemosensitivity: the role of O6 -methylguanine DNA methyltransferase in human cancer." 
Oncogene 23: 1.  
 
Esteller, M., M. Toyota, M. Sanchez -Cespedes, G. Capella, M. A. Peinado, D. N. Watkins, J. -P. J. 
Issa, D. Sidransky, S. B. Baylin and J. G. Herman (2000). "Inactivation of the DNA Repair 
Gene &lt;em&gt;O&lt;/em&gt;&lt;sup&gt;6&lt;/sup&gt; -&lt;em&gt;Methylguanine- DNA 
Methyltransferase&lt;/em&gt; by Promoter Hypermeth ylation Is Associated with G to A 
Mutations in &lt;em&gt;K -ras&lt;/em&gt; in Colorectal Tumorigenesis." Cancer Research  
60(9): 2368.  
 
Farago, A. F., B. J. Drapkin, A. Charles, B. Y. Yeap, R. S. Heist, C. G. Azzoli, D. M. Jackman, J. P. 
Marcoux, D. A. Barbie, D. T. Myers, S. Phat, J. Zhong, J. B. Grinnell, L. V. Sequist, M. Mino -
Kenudson, S. Maheswaran, D. A. Haber, A. N. Hata, N. J. Dyso n and A. T. Shaw (2018). "Safety 
and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer 
(SCLC)." Journal of Clinical Oncology  36(15_suppl): 8571- 8571.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 74 (94)   
Figueroa, M. E. (2010). "Leukemic IDH1 and IDH2 mutations result in a hypermethylation 
phenotype, disrupt TET2 function, and impair hematopoietic differentiation." Cancer cell  
18(6): 553- 567.  
 
Fulton, B., S. C. Short, A. James, S. Nowicki, C. McBain, S. Je fferies, C. Kelly, J. Stobo, A. Morris, 
A. Williamson and A. J. Chalmers (2017). "PARADIGM -2: Two parallel phase I studies of 
olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treat ment stratified by MGMT status." Clinical and 
translational radiation oncology  8: 12- 16. 
 
Gill, S. J., J. Travers, I. Pshenichnaya, F. A. Kogera, S. Barthorpe, T. Mironenko, L. Richardson, C. H. Benes, M. R. Stratton, U. McDermott, S. P. Jackson and M. J. Garnett (2015). "Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma." PLoS ONE  10(10): e0140988.  
 
Hegi, M. E. (2005). "Gene Silencing and Benefit from Temozolomide in Glioblastoma." The 
New England journal of medicine 352(10): 997 -1003.  
 
Hermisson, M. (2006). "O6- methylguanine DNA methyltransferase and p53 status predict 
temozolomide sensitivity in human malignant glioma cells." Journal of neurochemistry  
96(3): 766- 776.  
 
Hochhauser, D., R. Glynne -Jones, V . Potter, C. Gravalos, T. J. Doyle, K. Pathiraja, Q. Zhang, L. 
Zhang and E. A. Sausville (2013). "A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6 -
methylguanine- DNA methyltransf erase promoter." Mol Cancer Ther  12(5): 809- 818.  
 
Hughes, L. A. E., V. Melotte, J. de Schrijver, M. de Maat, V. T. H. B. M. Smit, J. V. M. G. Bovée, P. J. French, P. A. van den Brandt, L. J. Schouten, T. de Meyer, W. van Criekinge, N. Ahuja, J. G. Herman, M. P. Weijenberg and M. van Engeland (2013). "The CpG Island Methylator Phenotype: What&#039;s in a Name?" Cancer Research  73(19): 5858.  
 
Jagtap, P. and C. Szabó (2005). "Poly(ADP- ribose) polymerase and the therapeutic effects of 
its inhibitors." Nature Reviews Drug Discovery 4: 421.  
 
Javle, M., T. Bekaii‐ Saab, A. Jain, Y. Wang, K. Kelley Robin, K. Wang, C. Kang Hyunseon, D. 
Catenacci, S. Ali, S. Krishnan, D. Ahn, G. Bocobo Andrea, M. Zuo, A. Kaseb, V. Miller, J. 
Stephens Philip, F. Meric ‐Bernstam, R. Shroff and J. Ross (2016). "Biliary cancer: Utility of 
next‐generation sequencing for clinical management." Cancer  122(24): 3838- 3847.  
 
Konduri, S. D. (2009). "Blockade of MGMT expression by O6 benzyl guanine leads to 
inhibition of pancreatic cancer growth  and induction of apoptosis." Clinical cancer research  
15(19): 6087 -6095.  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 75 (94)  Kulke, M. H. (2009). "O6- methylguanine DNA methyltransferase deficiency and response to 
temozolomide -based therapy in patients with neuroendocrine tumors." Clinical cancer 
research  15(1): 338- 345.  
 
Lavin, M. F. (2008). "Ataxia -telangiectasia: from a rare disorder to a paradigm for cell 
signalling and cancer." Nature Reviews Molecular Cell Biology  9: 759.  
 
Le, D. T., J. N. Durham, K. N. Smith, H. Wang, B. R. Bartlett, L. K. Aulakh, S. Lu, H. Kemberling, 
C. Wilt, B. S. Luber, F. Wong, N. S. Azad, A. A. Rucki, D. Laheru, R. Donehower, A. Zaheer, G. A. Fisher, T. S. Crocenzi, J. J. Lee, T. F. Greten, A. G. Duffy, K. K. Ciombor, A. D. Eyring, B. H. Lam, A. Joe, S. P. Kang, M. Holdhoff, L. Danilova, L. Cope, C. Meyer, S. Zhou, R. M. Goldberg, D. K. 
Armstrong, K. M. Bever, A. N. Fader, J. Taube, F. Housseau, D. Spetzler, N. Xiao, D. M. Pardoll, 
N. Papadopoulos, K. W. Kinzler, J. R. Eshleman, B. Vogelstein, R. A. Anders and L. A. Diaz (2017). "Mismatch repair deficiency predicts response of solid tumors to PD -1 blockade." 
Science 357(6349): 409- 413.  
 
Le, D. T., J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling, A. D. Eyring, A. D. Skora, B. S. Luber, N. S. Azad, D. Laheru, B. Biedrzycki, R. C. Donehower, A. Zaheer, G. A. Fisher, T. S. 
Crocenzi, J. J. Lee, S. M. Duffy, R. M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R. H. Hruban, L. D. Wood, N. Cuka, D. M. Pardoll, N. Papadopoulos, K. W. Kinzler, S. 
Zhou, T. C. Cornish, J.  M. Taube, R. A. Anders, J. R. Eshleman, B. Vogelstein and L. A. J. Diaz 
(2015). "PD -1 Blockade in Tumors with Mismatch -Repair Deficiency." New England Journal 
of Medicine 372(26): 2509- 2520.  
 
Letouze, E., C. Martinelli, C. Loriot, N. Burnichon, N. Abermil , C. Ottolenghi, M. Janin, M. 
Menara, A. T. Nguyen, P. Benit, A. Buffet, C. Marcaillou, J. Bertherat, L. Amar, P. Rustin, A. De 
Reynies, A. P. Gimenez -Roqueplo and J. Favier (2013). "SDH mutations establish a 
hypermethylator phenotype in paraganglioma." Ca ncer Cell  23(6): 739- 752.  
 
Liu, L., L. Yan, J. R. Donze and S. L. Gerson (2003). "Blockage of abasic site repair enhances antitumor efficacy of 1,3 -bis-(2-chloroethyl) -1-nitrosourea in colon tumor xenografts." 
Molecular Cancer Therapeutics  2(10): 1061 -1066.  
 Loupakis et al 2014  
 
Loupakis, F., C. Cremolini, G. Masi, S. Lonardi, V. Zagonel, L. Salvatore, E. Cortesi, G. 
Tomasello, M. Ronzoni, R. Spadi, A. Zaniboni, G. Tonini, A. Buonadonna, D. Amoroso, S. 
Chiara, C. Carlomagno, C. Boni, G. Allegrini, L. Boni and A. Falcone (2014). "I nitial Therapy 
with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer." New England Journal 
of Medicine 371(17): 1609- 1618.  
 
Luo, M. (2004). "Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of br east cancer cells to DNA alkylating agents with 
lucanthone." Anticancer research  24(4): 2127.  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 76 (94)  Morano, F., S. Corallo, M. Niger, L. Barault, M. Milione, R. Berenato, R. Moretto, G. Randon, M. 
Antista, A. Belfiore, A. Raimondi, F. Nichetti, A. Martinetti, L . Battaglia, F. Perrone, G. 
Pruneri, A. Falcone, M. Di Bartolomeo, F. de Braud, F. Di Nicolantonio, C. Cremolini and F. 
Pietrantonio (2018). "Temozolomide and irinotecan (TEMIRI regimen) as salvage 
treatment of irinotecan -sensitive advanced colorectal canc er patients bearing MGMT 
methylation." Annals of Oncology : mdy197- mdy197.  
 
Murai, J., S.- y. N. Huang, B. B. Das, A. Renaud, Y. Zhang, J. H. Doroshow, J. Ji, S. Takeda and Y. 
Pommier (2012). "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors." Cancer 
Research  72(21): 5588- 5599.  
 
Murai, J., Y. Zhang, J. Morris, J. Ji, S. Takeda, J. H. Doroshow and Y. Pommier (2014). "Rationale for Poly(ADP- ribose) Polymerase (PARP) Inhibitors in Combination Therapy 
with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition." Journal of Pharmacology and Experimental Therapeutics  349 (3): 408- 416.  
Nagel, Z. D., G. J. Kitange, S. K. Gupta, B. A. Joughin, I. A. Chaim, P. Mazzucato, D. A. Lauffenburger, J. N. Sarkaria and L. D. Samson (2017). "DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme." Cancer Research  77(1): 
198- 206.  
 
Noushmehr, H. (2010). "Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma." Cancer cell  17(5): 510- 522.  
 
Ohmoto, A. and S. Yachida (2017). "Current status of poly(ADP- ribose) polymerase 
inhibitors and future directions." OncoTargets and therapy  10: 5195- 5208.  
 
Palma, J. P., Y. -C. Wang, L. E. Rodriguez, D. Montgomery, P. A. Ellis, G. Bukofzer, A . Niquette, 
X. Liu, Y. Shi, L. Lasko, G.- D. Zhu, T. D. Penning, V. L. Giranda, S. H. Rosenberg, D. J. Frost and 
C. K. Donawho (2009). "ABT -888 Confers Broad <em>In vivo</em> Activity in 
Combination with Temozolomide in Diverse Tumors." Clinical Cancer Research  15(23): 
7277- 7290.  
 
Pietrantonio, F., F. de Braud, M. Milione, C. Maggi, R. Iacovelli, K. F. Dotti, F. Perrone, E. Tamborini, M. Caporale, R. Berenato, G. Leone, A. Pellegrinelli, I. Bossi, F. Festinese, S. Federici and M. Di Bartolomeo (2016). "Dose- Dense Temozolomide in Patients with MGMT -
Silenced Chemorefractory Colorectal Cancer." Target Oncol  11(3): 337 -343.  
 
Pietrantonio, F., F. Perrone, F. de Braud, A. Castano, C. Maggi, I. Bossi, A. Gevorgyan, P. Biondani, M. Pacifici, A. Busico, M. Gariboldi, F. Festinese, E. Tamborini and M. Di Bartolomeo (2014). "Activity of temozolomide in patients with advanced chemoref ractory 
colorectal cancer and MGMT promoter methylation." Ann Oncol  25(2): 404- 408.  
 
Pishvaian, M. J., R. S. Slack, W. Jiang, A. R. He, J. J. Hwang, A. Hankin, K. Dorsch ‐Vogel, D. 
Kukadiya, L. M. Weiner, J. L. Marshall and J. R. Brody "A phase 2 study of t he PARP inhibitor 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 77 (94)  veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal 
cancer." Cancer  0(0). 
Pommier, Y., M. J. O’Connor and J. de Bono (2016). "Laying a trap to kill cancer cells: PARP 
inhibitors and their mechanisms of ac tion." Science Translational Medicine 8 (362): 
362ps317- 362ps317.  
 
Ryan, D. P. (2014). "Pancreatic Adenocarcinoma." The New England journal of medicine 
371(11): 1039- 1049.  
 
Sartore -Bianchi, A., F. Pietrantonio, A. Amatu, M. Milione, A. Cassingena, S. Ghezzi, M. 
Caporale, R. Berenato, C. Falcomata, A. Pellegrinelli, A. Bardelli, M. Nichelatti, F. Tosi, F. De Braud, F. Di Nicolantonio, L. Barault and S. Siena (2017). "Digital PCR assessment of MGMT 
promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients." Eur J Cancer  71: 43-
50. 
 
Shacham- Shmueli, E., A. Beny, R. Geva, A. Blachar, A. Figer and D. Aderka (2011). "Response 
to Temozolomide in Patients With Metastatic Colorectal Cancer With Loss of MGMT Expression: A New Approach in the Era of Personalized Medicine?" Journal of Clinical 
Oncology  29(10): e262- e265.  
 
Shen, J., Y. Peng, L.  Wei, W. Zhang, L. Yang, L. Lan, P. Kapoor, Z. Ju, Q. Mo, M. Shih Ie, I. P. 
Uray, X. Wu, P. H. Brown, X. Shen, G. B. Mills and G. Peng (2015). "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors." Cancer 
Discov  5(7): 752- 767.  
 
Smith, M. A., C. P. Reynolds, M. H. Kang, E. A. Kolb, R. Gorlick, H. Carol, R. B. Lock, S. T. Keir, J. M. Maris, C. A. Billups, D. Lyalin, R. T. Kurmasheva and P. J. Houghton (2015). "Synergistic 
Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric 
Cancer Models in the Pediatric Preclinical Testing Program." Clinical Cancer Research  
21(4): 819- 832.  
 
Suehiro, Y., C. W. Wong, L. R. Chirieac, Y. Kondo, L. Shen, C. R. Webb, Y. W. Chan, A. S. Y. Chan, T. L. Chan, T. -T. Wu, A. Rashid, Y. Hamanaka, Y. Hinoda, R. L. Shannon, X. Wang, J. 
Morris, J. -P. J. Issa, S. T. Yuen, S. Y. Leung and S. R. Hamilton (2008). "Epigenetic -Genetic 
Interactions in the <em>APC/WNT, RAS/RAF</em>, and <em>P53</em> Pathways in 
Colorectal Carcinoma ." Clinical Cancer Research  14(9): 2560 -2569.  
 
Tentori, L., C. Leonetti, M. Scarsella, G. d’Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. 
Zupi, J. Zhang and G. Graziani (2003). "Systemic Administration of GPI 15427, a Novel Poly(ADP -Ribose) Polymer ase-1 Inhibitor, Increases the Antitumor Activity of 
Temozolomide against Intracranial Melanoma, Glioma, Lymphoma." Clinical Cancer 
Research  9(14): 5370 -5379.  
 Tentori, L., I. Portarena, E. Bonmassar and G. Graziani (2001). "Combined effects of 
adenovirus -mediated wild -type p53 transduction, temozolomide and poly (ADP- ribose) 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 78 (94)  polymerase inhibitor in mismatch repair deficient and non- proliferating tumor cells." Cell 
Death And Differentiation 8 : 457.  
 
Tentori, L., I. Portarena, P. Vernole, P. De Fabritiis, R. Madaio, A. Balduzzi, R. Roy, E. 
Bonmassar and G. Graziani (2001). "Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP- ribose) polymerase inhibitors on cel l growth, 
chromosomal aberrations and base excision repair components." Cancer Chemotherapy 
and Pharmacology  47(4): 361- 369.  
 
Thomas, A. (2017). "Temozolomide in the Era of Precision Medicine." Cancer research 
(Chicago, Ill.)  77(4): 823- 826.  
 
Thomas, A., M . Tanaka, J. Trepel, W. C. Reinhold, V. N. Rajapakse and Y. Pommier (2017). 
"Temozolomide in the Era of Precision Medicine." Cancer Research  77(4): 823- 826.  
 
Trivedi, R. N. (2005). "The role of base excision repair in the sensitivity and resistance to temo zolomide -mediated cell death." Cancer research (Chicago, Ill.)  65(14): 6394- 6400.  
Turcan, S. (2012). "IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype." Nature (London)  483(7390): 479 -483.  
 
van den Bent, M. J. (2013). "MGMT -STP 27 methylation status as predictive marker for 
response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951." Clinical cancer research  19(19): 5513 -5522.  
 
Walter, T. (2015). "O6- Methylguanine- DNA methyltransferase status in neuroendocrine 
tumours: prognostic relevance and association with response to alkylating agents." British 
journal of cancer  112(3): 523- 531.  
 
Wang, P., J. Wu, S. Ma, L. Zhang, J. Yao, K. A. Hoadley, M. D. Wilkerson, C. M. Perou, K. L. Guan, D. Ye and Y. Xiong (2015). "Oncometabolite D -2-Hydroxyglutarate Inhibits ALKBH DNA 
Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents." Cell  Rep  13(11): 
2353- 2361.  
 
Williamson, C. T., R. Miller, H. N. Pemberton, S. E. Jones, J. Campbell, A. Konde, N. Badham, R. Rafiq, R. Brough, A. Gulati, C. J. Ryan, J. Francis, P. B. Vermulen, A. R. Reynolds, P. M. Reaper, J. R. Pollard, A. Ashworth and C. J . Lord (2016). "ATR inhibitors as a synthetic lethal therapy 
for tumours deficient in ARID1A." Nat Commun  7: 13837.  
 
Yan, L., A. Bulgar, Y. Miao, V. Mahajan, J. R. Donze, S. L. Gerson and L. Liu (2007). "Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase IIα." Clinical Cancer Research  13(5): 1532 -
1539.  
 
Yang, Y. -G., U. Cortes, S. Patnaik, M. Jasin and Z. -Q. Wang (2004). "Ablation of PARP- 1 does 
not interfere with the repair of DNA double -strand breaks, but compromises the 
reactivation of stalled replication forks." Oncogene 23: 3872.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 79 (94)   
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 80 (94)  11. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 81 (94)  Appendix  A Actions required in cases of increases in liver biochemistry and 
evaluation of Hy’s Law  
A 1 Introduction  
This Appendix describes the process to be followed in order to identify and appropriately report 
cases of Hy’s Law .  It is not intended to be a comprehensive guide to the management of 
elevated liver biochemistries .   
During the cours e of the study the Investigator will remain vigilant for increases in liver 
biochemistry .  The Investigator is responsible for determining whether a patient  meets potential 
Hy’s Law (PHL) criteria at any point during the study.  
The Investigator participates, together with AstraZeneca clinical project representatives, in review and assessment of cases meeting PHL criteria to agree whether Hy’s Law (HL) criteria are met .  HL criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry oth er than drug induced liver injur y (DILI) caused by the investigational medicinal 
product s (IP).   
The Investigator is responsible for recording data pertaining to PHL/HL cases and for reporting 
Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome of the review 
and assessment in line with standard safety reporting processes.  
A 2 Definitions 
Potential Hy’s Law (PHL)  
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3×  upper limit of normal  
(ULN) together with  total bilirubin  (TBL) ≥ 2 ×ULN at any point during the study following the 
start of study medication  irrespective of an increase in alkaline phosphatase (ALP) .   
Hy’s Law (HL)  
AST or ALT ≥ 3 ×  ULN together with TBL ≥ 2 ×ULN, where no other reason, other than the 
IMP, can be found to explain the combination of increases, eg , elevated ALP indicating 
cholestasis, viral hepatitis, another drug .   
For PHL and HL the elevation in transaminases must precede or be coincident with  (ie, on the 
same day) the elevation in TBL, but there is no specified time  frame within which the elevations 
in transaminases and TBL must occur.  
A 3 Identification of potential Hy’s Law cases  
In order to identify cases of PHL it is important to perform a comprehensive review of laboratory data for any patient  who meets any of the following identification criteria in isolation or in 
combination:  
• ALT ≥ 3 × ULN  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 82 (94)  • AST ≥ 3 ×  ULN  
• TBL ≥ 2 ×  ULN  
When a patient  meets any of the identification criteria, in isolation or in combination, the central 
laboratory will immediately send an alert to the Principal Investigator .   
The Investigator will also remain vigilant for any local laboratory reports where the 
identification criteria are met  without an alternative explanation , where this is the case the 
Investigator will: 
• Notify the AstraZeneca representative  
• Request a repeat of the test (new blood draw) by the central laboratory  
• Complete the appropriate unschedul ed laboratory CRF module(s) with the original 
local laboratory test result  
When the identification criteria are met from central or local laboratory results the Investigator 
will without delay:  
• Determine whether the patient  meets PHL criteria (see Appendix  A 2 for definition) by 
reviewing laboratory reports from all previous visits (including both central and local laboratory results)  
The Investigator will without delay review each new laboratory r eport and if the identification 
criteria are met  and there is no alterative explanation the investigator  will: 
• Notify the AstraZeneca representative  
• Determine whether the patient  meets PHL criteria (see Appendix  A 2 for definition) by 
reviewing laboratory reports from all previous visits  
• Promptly enter the laboratory data into the laboratory CRF  
A 4 Follow -up 
A 4.1 Potential Hy’s Law criteria not met  
If the pa tient does not meet PHL criteria the Investigator will:  
• Inform the AstraZeneca representative that the patient  has not met PHL criteria.  
• Perform follow -up on subsequent laboratory results according to the guidance 
provided in the Clinical Study Protocol. 
A 4.2 Potential Hy’s Law criteria met 
If the patient  does meet PHL criteria the Investigator will: 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 83 (94)  Determine whether PHL criteria were met at any study visit prior to starting Study treatment  
(See Section  8.4 Safety Reporting)  
• Notify the AstraZeneca representative who will then inform the central Study Team  
The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patient s’ follow -up and the continuous review of data .  Subse quent to this 
contact the Investigator will:  
• Monitor the patient  until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically indicated  
• Investigate the aetiology  of the event and perform diagnostic investigations as 
discussed with the Study Physician .  
• Complete the three Liver CRF Modules as information becomes available  
• If at any time (in consultation with the Study Physician the PHL case meets serious criteria,  report it as an SAE using standard reporting procedures.  
A 5 Review and assessment of potential Hy’s Law cases  
The instructions in this s ection should be followed for all cases where PHL criteria are met.  
No later than 3 weeks after the biochemistry abnormali ty was initiall y detected, the Study 
Physician  contacts the Investigator in order to review available data and agree on whether there 
is an alternative explanation for meeting PHL criteria other than DILI caused by the IMP .  The 
AstraZeneca Global Clinical  Lead or equivalent and Global Safety Physician will also be 
involved in this review together with other patient  matter experts as appropriate.   
According to the outcome of the review and assessment, the Investigator will follow the instructions below. 
If there is an agreed alternative explanation for the ALT or AST and TBL  elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE:  
• If the alternative explanation is not  an AE, record the alternative explanation on the 
appropriate CRF  
• If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF accordingly and follow the AZ standard processes  
If it is agreed that there is no explanation that would explain the ALT or AST and TBL elevations other than the IMP:  
• Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca standard processes .   
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 84 (94)  − The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply  
− As there is no altern ative explanation for the HL case, a causality assessment of 
‘related’ should be assigned. 
If there is an unavoidable delay of over 3 weeks in obtaining the information necessary to assess whether or not the case meets the criteria for HL, then it is assum ed that there is no alternative 
explanation until such time as an informed decision can be made:  
• Report an SAE (report term ‘Potential Hy’s Law’) applying serious criteria and causality assessment as per above  
• Continue follow -up and review according to agr eed plan .  Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine whether HL criteria are met .  Update the SAE report according to the outcome of the 
review amending the reported term if an alternative explanation for the liver biochemistry elevations is determined.  
A 6 Actions required when potential Hy’s Law criteria are met before and 
after starting study treatment  
This section is applicable to patient s liver metastases who meet PHL criteria on Study treatment  
having previously met PHL criteria at a study visit prior to starting Study treatment . 
At the first on -study treatment  occurrence of  PHL criteria being met , the Investigator will 
determine if there has been a significant change in the patient s’ condition compared with the last 
visit where PHL criteria were met.  
• If there is no significant change , no action is required 
• If there is a significant change, notify the AstraZeneca representative, who will inform 
the central Study Team, then follow the subsequent process described in  
Appendix  B 5. 
• A ‘significant’ change in the patient ’s condition refers to a clinically relevant change 
in any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in combination, or a clinically relevant change in associated symptoms .  
The determination of whether there has been a significant change will be at the discretion of the Investiga tor, this may be in consul tation with the Study Physician  if 
there is any uncertainty.  
A 7 Actions required for repeat episodes of potential Hy’s Law  
This section is applicable when a patient  meets PHL criteria on s tudy treatment, and has already 
met PHL crite ria at a previous on st udy treatment  visit.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 85 (94)  The requirement to conduct follow -up, review , and assessment of a repeat occurrence(s) of PHL 
is based on the nature of the alternative cause identified for the previous occurrence .   
The investigator should determine the cause for the previous occurrence of PHL criteria being 
met and answer the following question:  
Was the alternative cause for the previous occurrence of PHL criteria being met found to be the disease under stud y (eg, chronic or progressing malignant disease, severe infection or liver 
disease) , or did the subject  meet PHL criteria prior to starting s tudy treatment and at first on-
study treatment visit, as described in Appendix  A6. 
If No : Follow the process described in Appe ndix A 4.1. 
If Yes : Determine if there has been a significant change in the patient ’s condition compared with 
when PHL criteria were previously met . 
If there is no significant change , no action is requi red. 
If there is a significant change, follow the process described in Appendix  A 4. 
A ‘significant’ change in the patient ’s condition refers to a clinically relevant change in any of 
the individual liver biochemistry parameters (ALT, AST or total bilirubin) in is olation or in 
combination, or a clinically relevant change in associated symptoms .  The determination of 
whether there has been a significant change w ill be at the discretion of the Investigator; this may 
be in consultation with the AstraZeneca Physicia n if there is any uncertainty.  
  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 86 (94)  Appendix  B Adverse event definitions and additional safety information  
B1 Definition of adverse events 
An adverse event is the development of any untoward medical occurrence in a patient  or clinical 
study patient  administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment.   An AE can therefore be any unfavour able and unintended sign 
(e.g. an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease 
temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.   
The term AE is used to include both serious  and non- serious AEs and can include a deterioration 
of a pre -existing medical occurrence.  An AE may occur at any  time, including run -in or washout 
periods, even if no Study treatment has been administered.  
B2 Definitions of serious adverse event  
A seriou s adverse event is an AE occurring during any study phase (i.e., run- in, treatment, 
washout, follow -up), that fulfils one or more of the following criteria:  
12. Results in death  
13. Is immediately life -threatening 
14. Requires in -patient  hospitalisation or prolongation of existing hospitalisation  
15. Results in persistent or significant disability or incapacity.   
16. Is a congenital abnormality or birth defect  
17. Is an important medical event that may jeopardise the patient  or may require medical 
treatment to prevent one of the  outcomes listed above. 
B3 Life threatening  
‘Life -threatening’ means that the patient  was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the patient ’s 
death.  ‘Life -threaten ing’ does not mean that had an AE occurred in a more severe form it might 
have caused death (e.g., hepatitis that resolved without hepatic failure).  
B4 Hospitalisation  
Outpatient treatment in an emergency room is not in itself a serious AE, although the re asons for 
it may be (e.g., bronchospasm, laryngeal oedema).  Hospital admissions and/or surgical operations planned before or during a study are not considered AEs if the illness or disease 
existed before the patient  was enrolled in the study, provided tha t it did not deteriorate in an 
unexpected way during the study.  
B5 Important medical event or medical treatment  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 87 (94)  Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardize  the patient  or may require 
medical treatment to prevent one or more outcomes listed in the definition of serious.  These should usually be considered as serious.  
Simply stopping the suspect drug does not mean that it is an important medical event; medical judgement must be used.  
18. Angioedema not severe enough to require intubation but requiring iv hydrocortisone treatment  
19. Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with N -acetylcysteine  
20. Intensive treatment in an emergenc y room or at home for allergic bronchospasm  
21. Blood dyscrasias (e.g., neutropenia or anaemia requiring blood transfusion, etc.) or convulsi ons that do not result in hospitalisation  
22. Development of drug dependency or drug abuse  
B6 Intensity rating scale:  
The grading scales found in the revised National Cancer Institute CTCAE latest version (5.0) will be utilised for all events with an assigned CTCAE grading.  For those events without assigned CTCAE grades, the recommendation in the CTCAE criteria that conv erts mild, 
moderate and severe events into CTCAE grades should be used.  A copy of the CTCAE can be downloaded from the Cancer Therapy Evaluation Program website (http://ctep.cancer.gov). The applicable version of CTCAE should be described clearly.  
For eac h episode of an adverse event, all changes to the CTCAE grade attained as well as the 
highest attained CTC grade should be reported.  
It is important to distinguish between serious and severe AEs.  Severity is a measure of intensity 
whereas serio usness is d efined by the criteria in Appendix B2.  An AE of severe intensity need 
not necessarily be considered serious.  For example, nausea that persists for several hours may be 
considered severe nausea, but not a SAE unless it meets the criteria shown in Appendix  B2. On 
the other hand, a stroke that results in only a limited degree of disability may be considered a mild stroke but would be a SAE when it satisfies the criteria shown in Appendix B2. 
B7 A Guide to Interpreting the Causality Question  
When maki ng an as sessment of causality consider the following factors when deciding if there is 
a ‘reasonable possibility’  that an AE may have been caused by the drug.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 88 (94)  23. Time Course.  Exposure to suspect drug.  Has the patient  actually received the suspect 
drug?  Did the AE occur in a reasonable temporal relationship to the administration of 
the suspect drug?  
24. Consistency with known drug profile.  Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacolo gical class? Or could the AE be anticipated from its pharmacological 
properties?  
25. De-challenge experience.  Did the AE resolve or improve on stopping or reducing the 
dose of the suspect drug?  
26. No alternative cause.  The AE cannot be reasonably explained by another aetiology such as the underlying disease, other drugs, other host or environmental factors. 
27. Re-challenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally recommend or support a re-challenge.  
28. Laboratory tests.  A specific laboratory investigation (if performed) has confirmed the relationship . 
In difficult cases, other factors could be considered such as:  
29. Is this a recognized  feature of overdose of the drug?  
30. Is there a know n mechanism?  
Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a ‘reasonable possibility’ of a causal relationship for the individual case.  The expression ‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are facts (evidence) or arguments to suggest a causal relationship. 
The causality assessment is performed based on the available data including enough information 
to make an informed judgment.  With limited or insuff icient information in the case, it is likely 
that the event(s) will be assessed as ‘not related’.  
Causal relationship in cases where the disease under study has deteriorated due to lack of effect should be classified as no reasonable possibility.  
B8 Medica tion Error  
For the purposes of this clinical study a medication error is an unintended failure or mistake in the treatment process for an AstraZeneca study drug that either causes harm to the participant or has the potential to cause harm to the participant.   
A medi cation error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study site staff or participant.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 89 (94)  Medication error includes situations where an error.   
31. occurred  
32. was identified and intercep ted before the participant received the drug  
33. did not occur, but circumstances were recognize that could have led to an error  
 
Examples of events to be reported in clinical studies as medication errors:  
34. Drug name confusion  
35. Dispensing error e.g. medication p repared incorrectly, even if it was not actually given 
to the participant  
36. Drug not administered as indicated, for example, wrong route or wrong site of 
administration  
37. Drug not taken as indicated e.g. tablet dissolved in water when it should be taken as a 
solid tablet  
38. Drug  not stored as instructed e.g. kept in the fridge when it should be at room 
temperature  
39. Wrong participant received the medication (excluding IVRS/IWRS errors)  
40. Wrong drug administered to participant (excluding IVRS/IWRS errors)  
Examples of  events that do not  require reporting as medication errors in clinical studies: 
41. Errors related to or resulting from IVRS/IWRS -  including those which lead to one of 
the above listed events that would otherwise have been a medication error  
42. Participant acci dentally missed drug dose(s) e.g. forgot to take medication  
43. Accidental overdose (will be captured as an overdose)  
44. Participant failed to return unused medication or empty packaging 
45. Errors related to background and rescue medication, or standard of care medi cation in 
open label studies, even if an AZ product  
Medication errors are not regarded as AEs but AEs may occur as a consequence of the medication error.  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 90 (94)   
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 91 (94)  Appendix  C  Acceptable Birth Control Methods  
Olaparib is regarded as a compound with medium/high foetal risk.  
Women of childbearing potential and their partners, who are sexually active, must agree to the 
use of TWO highly effective forms of contraception in combination [as listed below].  This should be  started  from the signing of the informed  consent and continue  throughout the period of 
taking study treatment and for at least 6 months  after last dose of study drug(s), or they must 
totally/truly abstain from any form of sexual intercourse (see below).  
Male patients must use a condom during treatment and for 3 months after the last dose of 
olaparib when having sexual intercourse with a pregnant woman or with a woman of 
childbearing potential.   Female partners of male patients should also use a highly effective form 
of contraception if they are of childbearing potential (as listed below).  Male patients should not 
donate sperm throughout the period of taking olaparib and for 3 months following the last dose 
of olaparib.
 
Acceptable Non -hormonal birth control methods include:  
• Total/True abstinence: When the patient ref rains from any form of sexual intercourse and 
this is in line with their usual and/or preferred lifestyle; this must continue for the total 
duration of the trial and for at least 6 months  after the last dose of study drug and for 3 
months after last dose f or male patients . [Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post -ovulation methods, or declaration of abstinence solely for the 
duration of a trial) and withdrawal are not acceptable methods of contraception]  
• Vasectomised sexual part ner PLUS male condom.  With participant assur ance that 
partner received post -vasectomy confirmation of azoospermia. 
• Tubal occlusion PLUS male condom  
• IUD PLUS male condom.  Provided coils are copper -banded  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 92 (94)   
Acceptable hormonal methods:  
• Normal and low dose combined oral pills PLUS male condom  
• Cerazette (desogestrel) PLUS male condom.  Cerazette is currently the only highly 
efficacious progesterone based pill. 
• Hormonal shot or injection (eg., Depo -Provera) PLUS male condom  
• Etonogestrel implants (e.g., Implanon, Norplant) PLUS male condom  
• Norelgestromin / EE transdermal system PLUS male condom  
• Intrauterine system [IUS] device (eg., levonorgestrel releasing IUS -Mirena®) PLUS 
male condom  
• Intravaginal device (e.g., EE and etonogestrel) PLU S male condom  
 
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 93 (94)  Appendix  D ECOG Performance Status  
 
ECOG Performance Status Scale Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or 
sedentary nature ( e.g., light 
housework, office work).  80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time.  Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  60 Requires occasional assistance, but 
is able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated.  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
 
  
Clinical Study Protocol 11/23/20 – version 4.0 
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer    
CONFIDENTIAL AND PROPRIETARY 94 (94)   